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Abstract
The amount of biomedical literature has been increasing rapidly during
the last decade. Text mining techniques can harness this large-scale data,
shed light onto complex drug mechanisms, and extract relation information
that can support computational polypharmacology. In this work, we in-
troduce CASSANDRA, a fully corpus-based and unsupervised algorithm
which uses the MEDLINE indexed titles and abstracts to infer drug gene
associations and assist drug repositioning. CASSANDRA measures the
Pointwise Mutual Information (PMI ) between biomedical terms derived
from Gene Ontology (GO) and Medical Subject Headings (MeSH ). Based
on the PMI scores, drug and gene profiles are generated and candidate drug
gene associations are inferred when computing the relatedness of their pro-
files. Results show that an Area Under the Curve (AUC ) of up to 0.88
can be achieved. The algorithm can successfully identify direct drug gene
associations with high precision and prioritize them over indirect drug gene
associations. Validation shows that the statistically derived profiles from
literature perform as good as (and at times better than) the manually cu-
rated profiles. In addition, we examine CASSANDRA’s potential towards
drug repositioning. For all FDA-approved drugs repositioned over the last
5 years, we generate profiles from publications before 2009 and show that
the new indications rank high in these profiles. In summary, co-occurrence
based profiles derived from the biomedical literature can accurately predict
drug gene associations and provide insights onto potential repositioning
cases.
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Chapter 1
Motivation
Why Drug
Repositioning?
Drug discovery is an expensive and time-consuming process with a low rate
of success. The average cost for launching a new drug into the market is
estimated to 1.8 billion dollars (Paul et al., 2010) and the traditional time
line until a drug is made available for use ranges from 10-17 years. In spite
of that, the drugs that make it to the market are very few. Notably, from
1999 to 2008, only 50 compounds were approved by the Food and Drug Ad-
ministration (FDA) in the U.S., out of which 17 were identified as arising
from target-based discovery methods (Hurle et al., 2013). For these rea-
sons, drug repositioning constitutes a popular alternative to conventional
drug research and development for the past few years. Drug repositioning,
meaning the task of finding new targets for old drugs, accelerates the pro-
cess of drug development, minimizes the associated costs, and, in parallel,
contributes to the prevention of noxious adverse events and toxicological
liabilities. Via drug repositioning, abandoned drugs come back to use and
successful drugs expand their therapeutic applications.
Information
”hidden” in
literature
Knowledge pertaining to drug gene associations is considered valuable and
can contribute to drug discovery and repositioning. Unravelling putative
associations between drugs and gene products can shed light onto the pro-
cesses of drug delivery and its effects, such as the changes in the cellu-
lar metabolism and the occurrence of unexpected adverse events. Such
information is scattered across the biomedical literature, the volume of
which has been increasing rapidly during the past years. Computational
methodologies and more specifically text mining can harness the data that
1
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is publicly available in biomedical articles. With the help of Information
Extraction (IE ) techniques facts and arguments pertaining to drugs and
gene products can be retrieved. Linking this textual evidence can lead to
the inference of indirect relationships between drugs and genes and hence
support computational drug repositioning.
The Swanson
hypothesis
Generally, the inference of implicit knowledge from seemingly unrelated
facts has been called Literature-Based Discovery (LBD) (Andronis et al.,
2011). Literature-Based Discovery was successfully applied for the first
time on drug discovery by Don R. Swanson in 1986. Swanson spotted two
apparently unrelated facts that were reported separately in literature and
then brought them together in the formulation of a hidden hypothesis. The
first refers to the beneficial properties of fish oil towards the reduction of
blood viscosity. The second refers to high blood viscosity as a symptom of
a peripheral circulatory disorder known as Raynauds’ Syndrome. Swanson
generated the hypothesis that fish oil may have a beneficial effect towards
the alleviation of Raynauds’ Syndrome. This hypothesis was later experi-
mentally validated by the work of DiGiacomo et al. (1989).
The
contribution of
ontologies
Consequently, Information Extraction techniques and automated Literature-
Based Discovery constitute valuable tools towards the establishment of hid-
den hypotheses between biomedical entities and can be utilized to form pu-
tative associations between drugs and genes. To establish such associations,
as an analogous process to Swanson’s ABC model, the use of intermediate
biomedical concepts becomes critical; two unrelated concepts A and C (i.e.,
fish oil and Raynaud’s Syndrome) are indirectly connected via a concept
B (i.e., blood viscosity). Such concepts are provided by biomedical ontolo-
gies. Ontologies are hierarchically structured terminologies that capture
and formally represent knowledge as a set of concepts within a domain. In
the case of the biomedical domain, ontologies have been extensively used
towards three major directions: the management of biomedical knowledge,
the integration of data and the decision support and reasoning over the con-
cepts that constitute the ontologies (Bodenreider, 2008). Hence, biomedical
ontologies can be applied in tandem with the ABC model towards the ex-
traction of implicit knowledge and more specifically towards the retrieval
of potential drug gene associations.
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1.1 Problem definition and proposed approach
Mine implicit
drug gene
associations
The open problem that this work aims to address is the automated extrac-
tion of putative drug gene associations from biomedical text, as a way to
boost computational drug repositioning. The current study proposes the
application of standardized text mining techniques and the integration of
biomedical ontologies towards the identification of drug gene associations.
We mine the vast volume of biomedical literature to construct corpus-based
profiles of ontological terms for both genes and drugs. These profiles are,
then in turn used, to quantify the degree of relatedness between a drug and
a gene and hence to establish putative drug gene associations.
Ontological
co-occurrence
based profiles
More specifically, we introduce CASSANDRA; an unsupervised algo-
rithm that predicts new drug gene associations solely by the systematic
co-occurrence analysis of the biomedical terms in all the scientific publica-
tions indexed by MEDLINE. MEDLINE is a freely available bibliographic
database which contains journal citations and abstracts for biomedical lit-
erature from around the world. The presented method identifies the co-
occurrences of ontological concepts with drugs and genes in MEDLINE
titles and abstracts. The ontological terms are obtained from two popular
ontologies of the biomedical domain, i.e., the Gene Ontology (GO) (Ash-
burner et al., 2000) and Medical Subject Headings 1 (MeSH ). CASSAN-
DRA utilizes this co-occurrence information to rank the most related GO
and MeSH concepts to the drug and the gene respectively. These concepts
form an individual profile for each drug and gene. Then, by quantifying
the statistical semantic relatedness between these profiles, the suggested al-
gorithm assesses and prioritizes the associations between drugs and genes.
Notably, the generated profiles can provide an insight into biomedical prop-
erties for drugs and genes and contribute to the inference of associations
that might not have been included in a database nor reported in the liter-
ature.
1http://www.nlm.nih.gov/mesh/
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Figure 1.1: Overview of CASSANDRA
The figure illustrates the major steps of CASSANDRA. The first step involves
the recognition of drug and gene names, MeSH Disease and GO terms in the
biomedical text. Then in Step 2, ontological profiles are assigned to drugs and
genes, based on the Pointwise Mutual Information (PMI ) between drugs/genes
and ontological terms. The third step involves the computation of the statistical
semantic similarity between the ontological profiles. Finally, all pairs of a drug
Dx and a target gene Tx are ranked based on the semantic similarity of their
profiles.
1.2 Thesis Outline
The following thesis is structured in five main sections. In Chapter 2 (Back-
ground) the introduction of the thesis follows. In this section, we discuss
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the advances and applications of LBD along with the use of terminologies
towards the establishment of indirect hypotheses and the elucidation of hid-
den relations between biomedical entities. Additionally, relevant method-
ologies and algorithms towards the prediction of drug gene associations are
presented and compared based on their main characteristics.
Chapter 3 (Materials and Methods) describes the materials, text mining
tools terminologies and mathematical formulas that CASSANDRA uti-
lizes for the automatic identification of putative drug gene associations from
biomedical text. Apart from the information regarding the generation of
ontological profiles for drugs and genes and the computation of the statisti-
cal semantic relatedness between drugs and genes, the chapter includes the
resources and steps that were utilized for the generation of the evaluation
datasets.
In Chapter 4 (Results) the co-occurrence statistics of drugs, genes, MeSH
Disease and GO terms in MEDLINE indexed abstracts and titles are pro-
vided. The generation of the datasets used for the algorithm’s evaluation
and their content is analytically described. This section, provides exten-
sively detailed results that assess the good performance of the algorithm
for both literature based and manually curated profiles when tested on all
provided evaluation datasets. The proposed measure of semantic related-
ness is compared against other traditional measures of semantic similarity.
The role of ontologies in the overall performance is also examined. Addi-
tionally, Chapter 4 includes case studies of 3 manually evaluated drug gene
associations proposed by CASSANDRA. Results regarding the potential
of the suggested methodology towards drug repositioning are also provided.
Chapter 5 (Discussion) discusses the major characteristics of the algorithm.
The role of several factors and decisions taken during the algorithm’s imple-
mentation are being analyzed. CASSANDRA is compared against other
relevant works in the field of automatic Literature- Based Discovery and
drug target interaction prediction.
The thesis is concluded in Chapter 6 (Conclusion) wherein the major con-
tributions of CASSANDRA are summarized. This chapter also reports
the limitations and future optimizations of the suggested algorithm towards
the prediction of drug gene associations.

Chapter 2
Background
In this work we introduce CASSANDRA; an algorithm for the automated
extraction of candidate drug gene associations from biomedical text on the
large scale. CASSANDRA focuses on Literature Based Discovery and
utilizes standardized text mining techniques and ontologies to infer drug
gene associations and contribute to computational drug repurposing. This
chapter discusses the studies and scientific background that motivated the
implementation of CASSANDRA. More specifically, the following ques-
tions are addressed
• What is drug repositioning? Why is computational polypharmacol-
ogy important?
• What is Literature Based Discovery LBD? Which are the major prin-
ciples and studies in the LBD domain?
– Which is the role and contribution of biomedical ontologies?
– Which are the main methodologies towards information extrac-
tion from biomedical text?
• What is the state of the art in the field of computational drug gene
association prediction?
7
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2.1 Drug Repositioning
What is Drug
Repositioning
The Research and Developement (R&D) of new drugs is a particularly
time consuming and costly process. Despite the imminent effort of this
task, few are the drugs that finally make it to the market. Polypharmacol-
ogy (or Drug Repositioning) has lately entered the picture of drug research
and development and has been considered the means to overcome the com-
plexity, delays or possible deadlocks of this tedious process. Polypharma-
cology focuses on drug molecules that interact with multiple targets (Reddy
and Zhang, 2013). The old dogma of the Magic Bullet (one drug one tar-
get) introduced by Paul Erlich has been replaced by the one drug multiple
targets philosophy of polypharmacology. In particular, drug repositioning
focuses on the identification of unknown targets for already existing drugs,
thus presenting an alternative means in drug research and developement.
Figure 1.1 demonstrates a comparison between conventional drug research
and development and drug repurposing (Ashburn and Thor, 2004).
Drug repositioning emerged as a new paradigm after the discovery of drugs
with multi-targeting activities that could have either a therapeutic or nox-
ious effect. Such cases are quite a few.
Expand uses of
successful
agents
Notably, the story of drug repositioning dates back almost 60 years. A very
old case is that of the drug Plaquenil. Plaquenil (Hydroxychloroquine) has
been used in the beginning of the 20th century as an antimalarial agent. In
1955, Plaquenil was approved by the U.S. Food and Drug Administration
(FDA 1) for the treatment of Lupus Erythematosus, a multicomplex au-
toimmune disease of unknown etiology. Due to its immunosuppressive, an-
tiinflammatory and antithrombotic properties, Plaquenil has become since
then the most commonly prescribed antimalarial medication for Lupus in
the U.S. (Fessler et al., 2005). Perhaps the most famous repositioning case
is that of the drug Sildenafil (Viagra). Sildenafil was initially synthesised as
an therapeutic agent against Erectile Dysfunction and was FDA-approved
in 1998. Nevertheless, the efficacy of Sildenafil in the treatment of Pul-
monary Arterial Hypertension (PAH ) led to the extension of its approved
application in 2005 (Richalet et al., 2005).
12
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Figure 2.1: Drug repositioning vs. conventional drug development
De novo drug discovery and development is a 10 to 17 year process with a
probability of success lower than 10%. Drug repositioning offers the possibility
of reduced time and risk as several phases common to de novo drug discovery and
development can be bypassed because repositioning candidates have frequently
been through several phases of development for their original indication (Ashburn
and Thor, 2004).
Bring old
drugs back to
life
Another interesting repositioning case is that of the drug Thalidomide.
Thalidomide entered the market on 1957 as a sedative drug and it was
used to alleviate morning sickness and nausea in pregnant women. How-
ever, the latter led to unprecedented ramifications. Worldwide, there were
around 10, 000 cases of children born with limb malformation and other
developmental defects which were attributed to Thalidomide’s use. There
has been a long study regarding the etiology behind the teratogenic effects
of Thalidomide. Finally, in 2010 it became known that Thalidomide targets
and inactivates the protein Cereblon (CRBN ) which is important for the
limb outgrowth and expression of the fibroblast growth factor Fgf8. (Ito
et al., 2010). Despite the unwanted effects, the antiinflammatory proper-
ties of Thalidomide made the drug re-emerge as a therapeutic agent against
Erythema Nodosum Leprosum (ENL). FDA approved the respective use of
the drug in 1998 and 8 years later, in 2006, granted Thalidomide as the
first-line medication in the treatment of a specific type of bone marrow
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cancer, i.e., Multiple Myeloma (MM ). Thalidomide was found to inhibit
adhesion of Multiple Myeloma to bone marrow stromal cells and thereby
decreases tumor cell growth, survival and drug resistance conferred by the
bone marrow milieu. (Breitkreutz and Anderson, 2008).
Unravel
unwanted
adverse events
However, there are cases wherein the one drug-multiple targets philosophy
has fired back, leading to serious toxicological liabilities and the subsequent
withdrawal of a drug from the market. Alatrofloxacin constitutes a rep-
resentative example; manufactured as a potent antibiotic, the drug was
found to cause severe liver toxicity, even of lethal outcome (Qureshi et al.,
2011). Fatal Rhabdomyolysis was the unwanted adverse event after the
administration of Cerivastatin. The drug was initially developed to pre-
vent Cardiovascular Disease by reducing the levels of cholesterol. However,
its use was followed up by the decomposition of damaged muscle tissue, a
condition known as Rhabdomyolysis (Psaty, Bruce M. et al., 2004).
The examples described above demonstrate the broad range of prospects
related to drug repurposing. Identifying unknown targets for existing drugs
can expand the therapeutic applications of the successful agents (e.g., the
cases of Plaquenil and Sidenadelfil), bring abandoned compounds back
to life (as in the case of Thalidomide) or unravel any unwanted adverse
events (such in the case of Alatrofloxacin and Cerivastatin). In parallel,
the benefits in the financial and timescale related demands of drug research
and development are evident, thus making drug repurposing a desirable
alternative.
However, a plausible question arises; how feasible is it to cover all possible
targets on an experimental full-scale level, and thus enable drug repurpos-
ing? This fact poses an significant limitation to polypharmacology and
that is exactly wherein the computational methods come into play. In
the following section, we discuss the progress and efforts in the domain of
computational polypharmacology.
2.1.1 Computational polypharmacology
As it has been mentioned above, drug repositioning poses an industry-wide
challenge towards the experimental identification of unknown drug targets
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and hidden drug functionalities. Current experimental approaches include
large scale -omic (genomic and proteomic) analyses, and siRNA screens.
The former examines the modifications in gene expression levels and the
post-translational products of genes to determine disease mechanisms and
drug responses (e.g., Kim et al. (2011)). The latter elucidates the role
of individual proteins (potential drug targets or off-targets) in the cell by
examining the impact that the silencing of their coding gene has on the
signal transduction (Jackson and Linsley, 2010). Although successfully
applied, the aforementioned approaches result in vast volumes of biomedical
information. Utilizing this information to enable drug discovery has, in
turn, posed a subsequent challenge in terms of time and complexity (Betz
et al., 2005). For that reason, computational methods that expedite drug
discovery have been in the spotlight lately.
Drug-Disease
methods
Although a new field of scientific interest, computational drug repurpos-
ing has been rapidly advancing and already counts several success stories.
Following two basic directions towards drug repurposing, the computa-
tional methods either harness disease/phenotypic similarities and result in
novel drug disease relations or take a leap further to identify the exact
unknown targets of a drug. A representative example of the former is
the Connectivity Map (Lamb et al., 2006). The Connectivity Map con-
stitutes a reference collection of gene expression profiles for 164 bioactive
small molecules (perturbagens) on four human cancer cells lines. Given a
gene signature query, the system uses pattern-matching algorithms to re-
turn a ranked list of strongly correlated to weakly correlated gene profiles
and hence, perturbagens. Drug molecules correspond to a gene expression
state and whether the gene signature query constitutes a drug or a disease
related phenotype, drug-drug or drug-disease relations can be suggested.
Sirota et al. (2011) expanded the application of the Connectivity Map and
included in their study gene expression profiles for 100 diseases. Based on
the hypothesis that a drug with a gene expression signature opposite to
that of a disease can be a therapeutic alternative towards the respective
disease, they systematically computed the negative similarity between drug
and disease gene expression profiles. Altogether, they resulted in individual
therapeutic predictions for 53 diseases. Most importantly, the aforemen-
tioned study resulted in the successful computational repurposing of the
anticonvulsant drug Topimarate to Inflammatory Bowel Disease (Dudley
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et al., 2011a). Experimental validation in rodents showed that Topiramate
significantly reduced gross pathological signs and microscopic damage in
primary affected colon tissue which constitute manifestations of the In-
flammatory Bowel Disease. In a recent study, Jin et al. (2014) modified
the scoring scheme of Connectivity Map and experimentally evaluated their
predictions synergistic activity of the drugs Trolox C and Cytisine for the
treatment of Diabetes, Type 2.
Drug-Target
methods
Emphasizing on target identification, Keiser et al. (2007) classified tar-
get proteins based on the set-wise chemical similarity among their ligands.
Given a drug query, the Similarity Ensemble Approach that they intro-
duced suggests these target proteins whose known ligands share common
chemical features with the respective drug. This approach, led to the find-
ing that the drug Methadone, apart from an µ-opioid receptor modulator,
is also a potent antagonist of the M3 muscarinic receptor. This finding was
also experimentally validated. Campillos et al. (2008) computationally ap-
plied the hypothesis that drugs causing the same adverse events may share
the same off-targets. The authors built a network of 1, 018 side effect-based
drug-drug connections and experimentally confirmed 13 nover drug-target
interactions. In a following study, Lounkine and colleagues introduced a
conversed approach and used target protein predictions to associate drugs
with unintended adverse events (Lounkine et al., 2012). They focused on a
set 656 marketed drugs and 73 targets with experimentally established as-
sociations to certain adverse events. Via the Similarity Ensemble Approach,
they calculated the drug-target similarity and then they assigned novel side
effects to drugs. Their work resulted in the experimental validation of 125
novel drug-target interactions.
The studies described above suggest the efficient contribution of computa-
tional methods to polypharmacology and particularly drug repositioning.
Their successful application to drug discovery has triggered a plethora of
following up studies that span accross different data types (structural, tex-
tual or transcriptional/genomic data) (Hurle et al., 2013) and combine
different strategies, e.g., networks, text mining, machine learning (Dud-
ley et al., 2011b). As the biomedical data grows, the necessity for such
methodologies grows, as well.
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2.2 Literature Based Discovery in the
Biomedical Domain
Literature Based Discovery has been defined as the process of (semi)-
automatic inference of implicit knowledge out of literature (Weeber et al.,
2005). The first and most indicative paradigm of literature-based hypoth-
esis was introduced by Don R. Swanson in 1986 (Swanson, 1986) (Figure
2.2).
Figure 2.2: The Swanson Hypothesis
“Beneficial effect of fish oil on 
blood viscosity in peripheral 
vascular disease”  
[Woodcock et al., 1984] 
 
Fish oil 
Blood viscosity 
“…blood was studied in 20 
patients with Raynaud 
syndrome… studies 
demonstrate increased blood 
viscosity …” 
 [Tietjen et al., 1975] 
Raynaud’s 
syndrome 
Blood viscosity 
Blood viscosity 
HYPOTHESIS 
Fish oil treats Raynaud’s Syndrome 
[Swanson, 1986] 
 
 
 
 
CONFIRMATION 
Clinical study by DiGiacomo et al. (1989) 
The figure illustrates the first successful application of the ABC model. Two
seemingly unrelated facts form the hypothesis that fish oil is a treatment al-
ternative to Raynaud’s Syndrome. The hypothesis was initially established by
Swanson (1986) and DiGiacomo et al. provided the experimental validation 3
years later.
The Swanson
Hypothesis
Swanson spotted two independent reported facts in literature that, nev-
ertheless, shared one common factor; blood viscosity. The former refers to
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Raynaud’s Syndrome, a circulatory disorder which exhibits excessively re-
duced blood flow to fingers and toes, and hence results in increased blood
viscosity (Tietjen et al., 1975). The latter reports that Dietary Fish Oil
appears to lower blood viscosity (Woodcock et al., 1984). Observing that
Raynaud’s Syndrome and Dietary Fish Oil had never been reported to-
gether in literature before, Swanson connected these two assertions and
formed the hypothesis that Dietary Fish Oil may have a beneficial effect
on Raynaud’s Syndrome. Indeed, this hypothesis was afterwards exper-
imentally validated by DiGiacomo et al. (1989). On the same fashion,
Swanson along with his colleague Smalheiser furtherly exploited the mutu-
ally isolated literatures and postulated several other hypotheses (Swanson,
1990; Swanson and Smalheiser, 1996, 1998). In one of them, they sug-
gested the therapeutic effects of Magnesium in Migraine (Swanson, 1988).
Although, this hypothesis has not been experimentally confirmed, empiri-
cal treatment of Migraine patients with Magnesium has shown promising
results (Mauskop and Varughese, 2012).
ABC model -
definition
Establishing indirect associations between two concepts A and C via an
intermediate concept B has been refered to either as the Swanson Hy-
pothesis or the ABC model. The ABC model has been repeatedly used
to discover hidden associations in the biomedical domain. The developed
methodologies are either used to recover the original hypotheses proposed
by Swanson (Cameron et al., 2013; Cohen et al., 2010a; Srinivasan, 2004;
Weeber et al., 2001), or they take a step further and establish new hypothe-
ses (Gramatica et al., 2014; Dong et al., 2014; Baker and Hemminger, 2010;
Ahlers et al., 2007; Srinivasan and Libbus, 2004; Wren et al., 2004; Weeber
et al., 2003). Weeber et al. (2005) elaborated further on the ABC model
and discriminated the Literature Based Discovery methods into closed and
open discovery methods. As shown in Figure 2.3 the open model, the con-
cepts A and C are given and the hypothesis of A’s connection to C has
to be established by the identification of intermediate concepts B. On the
other hand, the closed model focuses on the concept A and using this as a
starting point browses the intermediate concepts B that indirectly connect
it to various final concepts C.
ABC model -
tools and
algorithms
Several algorithms and automated tools have adopted the ABC model
to assist Literature Based Discovery in the biomedical domain (see Table
2.1). Smalheiser and Swanson were the first to provide ARROWSMITH, a
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Figure 2.3: The open and closed ABC model
The two representations of ABC model. (A) Closed discovery model: the con-
cepts A and B share an implicit connection if they are explicitly associated to
a common concept B. (B)Open discovery model: Concept A is indirectly con-
nected to several concepts C via a set of intermediate concepts B. Figure as in
Andronis et al. (2011).
closed discovery automated system (Smalheiser and Swanson, 1998). Us-
ing only the titles from the MEDLINE indexed articles and for two given
concepts A and C, ARROWSMITH retrieves the article sets pertaining to
A and B respectively and generates a set of intermediate terms B (i.e.,
words/phrases) that are found to overlap in these article sets. FACTA+
also utilizes MEDLINE and uses open discovery to retrieve indirect asso-
ciations between drugs, diseases, chemical compounds and proteins/genes
(Tsuruoka et al., 2011); the system accepts a set of keywords as a query
input and returns all possible directly associated concepts. It then uses
these so-called pivot concepts as intermediates and retrieves the directly
associated to them target concepts. The query can be either a single term
or a biomolecular event, whilst the query-pivot and pivot-target concept
relations are suggested based on co-occurrence statistics. Quite similar to
FACTA+ is the CoPub Discovery system (Frijters et al., 2010) which is
also based on co-occurrence statistics. CoPub Discovery supports both
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closed and open discovery between drugs, genes and diseases with the use
of biological processes, pathways and genes as the intermediate concepts.
Another automated tool supporting both open and closed discovery is
BITOLA (Hristovski et al., 2005). BITOLA uses a two step establishment
of indirect relationships between disease terms and genes. First, it estab-
lishes associations between diseases or genes and Medical Subject Headings
(MeSH ) 3 descriptors based on co-occurrence statistics. The higher the
number of MeSH descriptors connecting the disease term and the gene,
the stronger the implicit association between them. MeSH is a controlled
vocabulary created for indexing articles in the life sciences, whilst theMeSH
descriptors are the MeSH terms that are assigned to MEDLINE indexed
articles through manual curations. Such terms are used in the method-
ology of Baker and Hemminger (2010) wherein indirect associations are
established between fixed chemicals and disease terms via proteins.
Although, the majority of ABC model methodologies uses co-occurrence
statistics, there are a few methods that use Natural Language Processing
techniques to establish relationships between a concept A or C with an
intermediate concept B (Cairelli et al., 2013; Cohen et al., 2012, 2010a;
Hristovski et al., 2008). Table 2.1 provides an overview of the most distinc-
tive tools implemented for Literature Based Discovery. As shown, most of
the tools utilize MEDLINE, but few of them deviate from the traditional
ABC model. The majority remains to the hypothesis retrieval without ap-
plying any further refinement. Additionally, although ontologies constitute
useful resources of terms for the hypothesis establishment, these are not ex-
tensively used. The tools consider rather their own specified terminologies,
as in the case of CoPub Discovery for example.
The seminal ABC model goes beyond literature applications. Observing
things from a more general perspective, several works in the domain of
life sciences have generated hypotheses based on the implicit connections
between two entities. For example, Campillos et al. (2008) use side effects
as the intermediate concepts to relate drugs to targets. The Connectivity
Map can be also considered an expansion of the ABC model (Lamb et al.,
2006); the gene expression profiles are connecting two drugs or a drug with
a disease. WENDI is another tool that concentrates data from various
3http://www.nlm.nih.gov/mesh/
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biomedical repositories and uses this data to indirectly associate drugs
with genes and diseases (Zhu et al., 2010).
Text mining
and ontologies
for ABC
model
Apparently, two are the prerequisites when applying the ABC model on
the biomedical literature. The former is a set of terms/entities found in
text and the latter is to establish pairwise relations between them. Hence,
the arising questions are; which are the terms that are important for Lit-
erature Based Discovery in the biomedical domain? How can we extract
these terms an any existing pairwise relations between them? On the one
hand, there is the necessity for established dictionaries and structured ter-
minologies (ontologies) indexing the biomedical literature. On the other
hand, there is the necessity for text mining tools that are able to success-
fully spot the references of such terms in text and retrieve the relations
between them.
2.3 Biomedical Ontologies
Definition
In computer science, an ontology is defined as the technique used to rep-
resent and disseminate knowledge about a specific domain by modeling
the elements in that domain and the relationships between them (Gruber,
1991; Bodenreider and Stevens, 2006). According to Maojo et al. (2011),
ontologies involve: (a) modelling primitives that include objects, classes
or categories (e.g., cells, organs, persons), (b) semantic relationships be-
tween these primitives (e.g., kidney is part of human body), (c) properties
pertaining to each class (descriptive or functional).
The role of
biomedical
ontologies -
Indexing
Bodenreider (2008) classified the role of ontologies into three major cate-
gories. The first is the knowledge management, such as indexing and infor-
mation retrieval. For example, Medical Subject Headings (MeSH ) are used
to index the MEDLINE articles. Shah et al. (2009a) implement a proto-
type system for the automated annotation and indexing of gene-expression
data sets, image descriptions, clinical trial reports and MEDLINE indexed
abstracts with concepts from the appropriate ontologies. SemRep extracts
semantic predications (subject-predicate-object triples) from text based on
UMLS (Unified Medical Language System) concepts, (Rindflesch and Fisz-
man, 2003).
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Data
Integration
The second role is to integrate (heterogeneous) data and disseminate it.
A prerequisite for that is, of course, semantic interoperability. Gene On-
tology (GO) is such a resource (Ashburner et al., 2000). GO is a popular
and publicly available controlled vocabulary that concentrates information
regarding genes, gene products and their attributes. Its major goal is to
unify the genes’ representation across databases and provides tools that al-
low easy access to the GO data and annotations. Apart from gene annno-
tation, GO has also been used to structure MEDLINE indexed articles
and abstracts by the semantic knowledge-based search engine GoPubMed
(Doms and Schroeder, 2005).
Reasoning
The third role of ontologies is to assist decision support and automated
reasoning. Blonde et al. (2011) performed a semi-automated approach to
reason over different ontologies and managed to infer 158 million previ-
ously hidden knowledge statements. The Systematized Nomenclature of
Medicine-Clinical Terms (SNOMED CT ) 4 is a formalized comprehensive
terminology for the Electronic Health Record (EHR). Its formal model has
allowed reasoning services to derive implicit relations (subsumptions) from
the ones explicitly represented by automatically computing the axioms re-
sponsible for these relations (Baader and Suntisrivaraporn, 2008). In the
same context, Magka et al. (2014) implement a reasoning algorithm that
significantly speeds up the automated classification of the chemical com-
pounds included in the ChEBI (Chemical Entities of Biological Interest)
ontology and contribute to the ontology’s curation by identifying missing
and contradictory subsumptions.
Connect
biomedical
entities via
ontologies
Ontologies have been also used as means to establish or unravel relations
between biomedical terms and hence to assist information extraction. Srini-
vasan and Libbus (2004) were among the first to use the MeSH terms that
indexMEDLINE articles to establish topic profiles and generate hypotheses
similar to the Swanson example. Several methodologies have since then ex-
ploited profiles ofMeSH terms to interrelate biomedical entities (Baker and
Hemminger, 2010; Cheung et al., 2012, 2013; Dong et al., 2014). BioMine
collects data from several biomedical knowledge bases and, among others,
utilizes GO terms towards link prediction in a large network of biomedical
entities (Eronen and Toivonen, 2012). Schlicker et al. (2010) made a step
4http://www.ihtsdo.org/snomed-ct/snomed-ct0/
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further and prioritized disease-gene pairs based on the similarity of their
GO profiles. Plake (2010) apply an elementary version of the same idea
to relate drugs and genes. Sevelar studies have used phenotypic terminolo-
gies on that respect, as well (Oellrich et al., 2014; Smedley et al., 2013;
Washington et al., 2009). To extract drug target information, Hoehndorf
et al. (2013) compute the similarity between mouse model and drug-induced
phenotypes with the use of Mammalian Phenotype Ontology (MP) (Smith
et al., 2004) and the Human Phenotype Ontology (HPO) (Robinson et al.,
2008).
Semantic
similarity
metrics
As shown above, the relationships between biomedical entities (e.g., pro-
teins or diseases and genes) can be established via the same or similar
ontological concepts. Hence, a variety of metrics has been implemented to
assess the semantic similarity (relatedness) between two ontological con-
cepts. Pesquita et al. (2009) classify these metrics in two basic categories;
the edge-based and the node-based approaches. Edge-based approaches
mainly consider the similarity of two ontological terms as a function of the
distance between them in the ontology (Wu and Palmer, 1994; Leacock
et al., 1998); the shortest the path that connects the two terms via their
Least Common Ancestor (LCA), the higher their similarity. Node-based
approaches apart from hierarchical information also compare certain prop-
erties of the ontological terms, such as their Information Content (IC ) on
an specific corpus (Resnik, 1995; Jiang and Conrath, 1997; Lin, 1998; Couto
et al., 2005; Pesquita et al., 2008).
Several approaches have explicitly focused on GO. Wang et al. (2007) pro-
pose an edge-based similarity metric that considers the semantic contribu-
tion of each edge type (is part of or is a). Jain and Bader (2010) use the
number of a node’s descendants to formulate the topological Information
Content and cluster relative GO terms; terms that belong to the same
subset are assigned a higher similarity score. Yang et al. (2012) explore
the hierarchy beneath the GO terms and model the uncertainty of the
nodes based on gene annotation information to improve existing measures
of semantic similarity.
The ontologies mentioned above constitute only some popular examples.
Currently, there is a variety of biomedical ontologies covering certain sec-
tors of knowledge at different levels of specificity. For example, there are
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ontologies dedicated to a specific disease (e.g., the Cardiovascular Disease
Ontology or CVDO (Barton et al., 2014)), a specific type of cells (e.g.,
Beta Cells Genomic Ontology or BCGO (Zheng et al., 2013)) or a certain
organism (e.g., Xenopus Anatomy and Development or XAO (Segerdell
et al., 2013)). Several initiatives towards the formulation of a common set
of principles for different ontologies also exist, such as the Open Biomedi-
cal Ontologies (OBO) consortium (Smith et al., 2007). As the amount of
data produced in biology exponentially increases due to the advent of the
genomic era and the high-throughput techniques developed in sequencing,
drug and phenotypic screening, the role of ontologies becomes more and
more significant (Hoehndorf et al., 2012).
2.4 Mining biomedical text
Deciding which biomedical terms/ontological concepts to annotate in text
constitutes only the first step towards the extraction of information in the
biomedical domain. The successful identification of these very terms and
the extraction of any of their relationships reported in text are the fol-
lowing and particularly demanding steps. Given the exponential growth
of biomedical literature (Hunter and Cohen, 2006), the automation of this
process is itself a significant challenge. Accordingly, traditional biomedical
text mining systems usually consist of two modules; the former recognizes
biological entities or concepts in text and the latter focuses on the extrac-
tion of any relations existing between these entities (Zweigenbaum et al.,
2007).
Abstracts and
full-text
With regards to the biomedical text that constitutes the input of text
mining systems, scientific abstracts and titles are widely used mainly due
to their public accessibility through PubMed 5 (i.e., an interface to browse
the MEDLINE database of indexed articles in life sciences) (Vincze et al.,
2008). It has been also demonstrated that text mining tools perform bet-
ter in abstracts than in full-text articles (Cohen et al., 2010b). Gijo´n-
Correas et al. (2014) predict the relatedness of a list of chemicals retrieved
from MEDLINE indexed abstracts and titles to a query topic. GoPubMed
5http://www.ncbi.nlm.nih.gov/pubmed
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(Doms and Schroeder, 2005) and PubTator (Wei et al., 2013) are web-
tools that allow users to retrieve articles associated with specific biocon-
cepts based on their MEDLINE abstracts. LitInspector performs signal
transduction pathway mining again fromMEDLINE abstracts. PolySearch
combines abstracts and database factoids to unravel biomedical relations
(Cheng et al., 2008) Nevertheless, there exist methodologies that investigate
the extraction of biomedical information from full-text articles. In a recent
work, Ne´ve´ol et al. (2012) propose the use of text mining on full-text arti-
cles to tackle the automatic curation of links between biological databases
and the literature. Pharmspresso automatically extracts pharmacogenomic
facts from full text articles (Garten and Altman, 2009). Hakenberg et al.
(2010) focus on protein-protein interaction extraction from full-text arti-
cles. GeneView is a semantic search engine built upon a comprehensively
annotated version of MEDLINE abstracts and openly available full-text
articles (Thomas et al., 2012).
2.4.1 Annotation of Biomedical Terms
Term
categories and
approaches
The identification of terms in biomedical text is an active field of study.
There exist a variety of Name Entity Recognition tools often addressing spe-
cific terms categories. The most popular term category is that of genes/pro-
tein names (Campos et al., 2013; Fontaine et al., 2011; Torii et al., 2009;
Hakenberg et al., 2008a; Settles, 2005). There are also species/organism de-
tection methodologies like LINNAEUS (Gerner et al., 2010) which are com-
monly used together with gene/protein name annotators to alleviate the
high inter-species ambiguity that characterizes gene names. Other Named
Entity Recognition tools identify protein mutations (Burger et al., 2014;
Winnenburg et al., 2009; Caporaso et al., 2007) or disease names (Leaman
et al., 2013). Lately, there has been an effort to tackle annotation of text
with chemical names (Rockta¨schel et al., 2012; Jessop et al., 2011). Tools
and strategies have been also applied towards the annotation of ontologi-
cal terms in text (Aronson and Lang, 2010; Shah et al., 2009b; Doms and
Schroeder, 2005). Name Entity Recognition tools usually follow dictionary
based matching approaches combined with machine learning components
(Huang et al., 2011; Wermter et al., 2009). In some cases only machine
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learning (Leaman et al., 2013) or rule-based approaches are used (Kang
et al., 2012).
Challenges
Each term category entails its own challenges in the process of Name Entity
Recognition. For example, gene/protein names are characterized by ambi-
guity not only across species but also within species, with common English
words and with medical sublanguage terms (Wermter et al., 2009). Apart
from overlapping with gene names, disease names are frequently abbrevi-
ated when mentioned in text (Leaman et al., 2013). The case of chemical
name regognition poses an even greater challenge due to the highly hetero-
geneous and various ways of naming them (e.g., chemicals can be referred
to by their IUPAC (International Union of Pure and Applied Chemistry)
6 or brand name) (Rockta¨schel et al., 2012). The recognition of concepts
(ontological terms) in text involves an additional complication, since there
is often a disconnect between what is captured in an ontology and what is
found to be explicitly stated in text (Funk et al., 2014).
2.4.2 Relation Extraction
Types of
relations
After the identification of biomedical entities in text, the establishment of
the relations between them follows. Several methodologies are developed
to target usually one type of relations. For example, there are approaches
focusing in the retrieval of protein protein interactions (Hakenberg et al.,
2010; Jelier et al., 2005; Cohen et al., 2005), or point protein mutations
related to a specific disease (Burger et al., 2014; Doughty et al., 2011).
Other studies focus on gene-phenotype (Paik et al., 2014), drug-disease
(Cheung et al., 2013), disease-phenotype (Xu et al., 2013) or protein-ligand
associations (Chang et al., 2012).
Co-occurrence
Towards the establishment of relations between biomedical entities, there
are two basic approaches. The former is to retrieve relations based on
the terms co-occurrence statistics. This method builds on the assumption
that two entities found together in the same abstract or sentence/phrase
are likely to be related. In an early study, Jenssen et al. (2001) build a
gene-gene relationship network by weighting the co-occurrences of gene-
gene pairs in MEDLINE abstracts. Garten et al. (2010) learn drug-gene
6http://www.iupac.org/
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associations from a co-occurrence based network of drugs and genes also
built from MEDLINE abstracts. Paik et al. (2014) extract disease co-
occurrences from medical reports and show that there is a correlation be-
tween disease comorbidity and overlaping disease-related protein-protein
interactions. FACTA+, Pescador, Pharmspresso and GoGene are just
a few examples of tools that generate biomedical relations based on co-
occurrence data (Tsuruoka et al., 2011; Barbosa-Silva et al., 2011; Garten
and Altman, 2009; Plake et al., 2009).
Patterns/rules
The latter method to extract biomedical relations from text is to ap-
ply predefined or automatically generated patterns/rules. AutoBind is a
pattern-based method for the automated extraction of protein-ligand asso-
ciations (Chang et al., 2012). RelEx and OpenDMAP apply rules on de-
pendency parse trees to extract protein-protein interactions (Hunter et al.,
2008; Fundel et al., 2007). Cou (2010) also use dependency graph rules to
detect pharmacogenomic relations. EventMine learn predicate-argument
structures to extract biomolecular events from text (Miwa et al., 2012).
SemRep extracts semantic predications (subject-predicate-object triples)
from text between UMLS concepts (Rindflesch and Fiszman, 2003).
Pros & cons
Evidently, these strategies are extensively applied in relation extraction
and consequently, in Literature Based Discovery (see Table 2.1). However,
co-occurrence based statistics tend to be slightly more popular compared
to the pattern based strategies. This has several explanations. Unlike syn-
tactic patterns, co-occurrence based statistics are relatively easier to im-
plement and can be applied on the large scale without text pre-processing
requirements (Zweigenbaum et al., 2007). Additionally, they are domain-
independent. For example, it is impossible to use the same syntactic pat-
terns to retrieve a drug-disease relationship and a protein-protein interac-
tion. However, that very specificity of pattern-based approaches provide
the user with the exact type of relation between the entities and thus
opt for high precision. Ideally, the two methodologies combined produce
high quality results. Xu and Wang (2014) learn syntactic patterns over
automatically recovered occurrences of known drug-side effect pairs from
literature. In an earlier study Bunescu et al. (2006) use both strategies to
recover protein-protein interactions from text. Table 2.2 summarizes the
advantages and disadvantages of each approach.
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Table 2.2: Co-occurrence vs. Patterns
Co-occurrences Patterns/Rules
Fast Type of relation
Pros High recall High precision
Straightforward implementation
Text-preprocessing
No relation type Domain-dependent
Cons Low precision Low recall
Laborious generation
The table reports the advantages and disadvantages of co-occurrence based and
pattern-based relation extraction.
2.5 Drug gene association prediction
To assist computational drug repurposing, many methodologies have been
established towards the prediction of target proteins for drugs. Popular
strategies involve the use of side effect similarity (Campillos et al., 2008),
chemical structural similarity (Keiser et al., 2007) and protein structural
similarity (Kinnings et al., 2009) for the identification of drug repositioning
candidates. Other methodologies apply large scale molecular docking anal-
ysis of known drugs against known targets to identify off-target proteins
with novel scaffolds or proteins structurally dissimilar to known targets (Li
et al., 2011).
Type of data
Lately, many studies combine chemical structural and protein sequence
similarity to predict drug target interactions (van Laarhoven and Mar-
chiori, 2013; Mei et al., 2013; Fakhraei et al., 2013; Perlman et al., 2011;
Bleakley and Yamanishi, 2009). Towards the same direction, several works
use on top of that pharmacological effects similarity (e.g., side or therapeu-
tic indication), as well (Kim et al., 2013a; Yu et al., 2012; Yamanishi et al.,
2010). Notably, Takarabe et al. (2012) show that the use of pharmaco-
logical effects similarity of drugs in tandem with the genomic similarity of
targets in a pairwise kernel regression model achieves a better performance
than the use of chemical similarity and genomic similarity combined.
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Protein-protein interactions (PPI) networks have also come to play. Hansen
et al. (2009) rank human genes to a query drug by building on a local
network of known interactions and learning on the similarity of the query
drug (by both structure and indication) with drugs that interact with gene
products in the local network. Emig et al. (2013) combine a PPI network
with disease microarray data and learn both global and local features to
rank a disease signature against a set of drug targets.
Few
unsupervised
methods
Generally, there are very few unsupervised methods towards the prediction
of drug-gene associations. Chen et al. (2012) build a network of so-called
semantically linked entities to drugs based on publicly available repositories
which comprise drug-related information (i.e., pathway, side effect, disease
data). Based on the topology and semantics of the neighborhood, they
build a statistical model to infer drug-gene associations (edges) in the net-
work. Of course, this method depends on the information completeness of
the network; the more information (links) is known for a drug, the better
is the ability of the method to successfully predict its target. Wu et al.
(2012) harness the biomedical literature. They annotate drugs and genes
on a subset of MEDLINE abstracts and examine the performance of the
Latent Dirichlet Allocation towards the ranking of drug-gene associations
on different levels of co-occurrence.
Supervised
bipartite graph
methods
On the other hand, the supervised techniques for the prediction of drug-
gene associations are numerous (Alaimo et al., 2013; Chen and Zhang, 2013;
Mei et al., 2013; Yu et al., 2012; Perlman et al., 2011; Yamanishi et al.,
2010). The majority of them views the set of drug target interactions as a
bipartite graph, i.e., a graph where edges are only allowed to pass between
one class of nodes (drugs) and the other (targets). Bleakley and Yamanishi
(2009) were the first to use such a representation to predict drug-target
interactions (edges in the bipartite graph) via learned local models from
chemical and genomic data. In the same context, Fakhraei et al. (2013) and
Go¨nen (2012) train a probalistic model to predict edges on the bipartite
drug-target interaction (DTI) network.
Laarhoven et al. (2011) construct gaussian kernel functions from binary
interaction profile vectors for drugs and targets and show that the topology
of the bipartite DTI network is on its own a substantial source for predicting
drug-target interactions. Cheng et al. (2012a) also learn the topological
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DTI network similarity and demonstrate that Network Based Inference
performs better than Drug or Target based Inference towards the prediction
of new targets for known drugs. The latter is a limitation of the two
aforementioned approaches; when a drug lacks known target information,
it is not possible to predict new targets.
Other supervised methodologies apply the Nearest Neighbor algorithm to
predict new targets for drugs of unknown interaction information (van
Laarhoven and Marchiori, 2013; He et al., 2010). Wang and Zeng (2013)
train a two-layer graphical model to predict the type of interaction between
a drug and a target. Kim et al. (2013a) demonstrate that drug-drug inter-
action data is a contributing feature towards the prediction of drug-target
interactions. Gao et al. (2013) assign drugs to target groups based on the
associations of their ontogogical ChEBI terms. Other works learn from
chemogenomic and structural activity features (Cheng et al., 2012b).
Literature
features
unexplored
Notably, literature-based methods are limited. Zhu et al. (2005) learn from
gene-gene, compound-compound and gene-compound co-occurrence data
in MEDLINE abstracts and detect implicit gene-compound associations.
Garten et al. (2010) replaced the drug-gene network in Hansen et al. (2009)
by a gene-drug network derived from the sentence level co-occurrence of
drugs and genes in full-text articles. They show that the logistic regression
classifier trained on this network is as good as (and sometimes better than)
the one trained on the network built from manually curated knowledge
bases (i.e., the case in Hansen et al. (2009)). Plake (2010) presents an
early stage approach that relates drugs to genes via concepts derived from
MEDLINE. However, this work suffers from rudimentary evaluation; there
is no filtering of the concepts applied when establishing drug gene relations
and the dataset used for the evaluation fails to demonstrate the real efficacy
of the proposed method. Still, this work motivates the use of literature
towards drug gene association prediction.
To conclude, few are the literature based approaches towards the prediction
of drug gene associations. Moreover, the majority follows machine learning
techniques that integrate features from highly diverse data; chemical struc-
tures, target aminoacid sequences, pharmacogenomic or chemogenomic in-
formation, protein-protein interaction data or even disease microarray data
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(e.g., as in Emig et al. (2013)). Additionally, quite some of them are lim-
ited to predictions that consist of known targeted drugs and druggable
proteins (e.g., Laarhoven et al. (2011); Alaimo et al. (2013)). Table 2.3
provides the respective overview. In a recent study, Pahikkala et al. (2014)
revise the supervised methods towards drug-target interaction prediction
and pinpoint the drawbacks. Among others, they state that these models
are often being constructed and evaluated under overly simplified settings
that do not reflect the real-life problem in practical applications.
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Chapter 3
Materials and Methods
CASSANDRA utilizes the biomedical literature to identify latent rela-
tions between drugs and genes by creating their ontological profiles and
measuring their relatedness. This chapter reports the materials, text min-
ing methods and mathematical formulas that were utilized to implement
and evaluate CASSANDRA’s efficacy.
Regarding the implementation, the following questions are answered
• Which text is annotated? Which terms are searched in text?
• Which annotators are utilized for the recognition of terms in text?
• How are the drug and gene profiles generated?
• How is the semantic relatedness between the profiles estimated?
With respect to the algorithm’s evaluation:
• Which datasets are used?
• How are these datasets generated?
• Which alternative metrics of semantic similarity are compared against
the semantic relatedness metric utilized by CASSANDRA?
31
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3.1 Materials and Methods - Implementa-
tion
3.1.1 Resources - Text and terms
Biomedical text
CASSANDRA mines the abstracts and titles of MEDLINE indexed ar-
ticles to establish latent drug gene associations. The MEDLINE database
is a freely available bibliographic repository which contains journal cita-
tions, abstracts and full-body articles of biomedical literature from around
the world. Currently, MEDLINE comprises around 24 million records.
However, only ∼ 2% of MEDLINE entries have open-access full-text ar-
ticles available for text mining (Thomas et al., 2012). For that reason,
CASSANDRA utilizes only the abstracts and titles of approximately 23
million biomedical articles that were available at the time of the algorithm’s
implementation (March 2013).
Biomedical terms
CASSANDRA searches for hidden indirect associations between drugs
and genes. Each drug and each gene are assigned an ontological profile that
consists of terms derived from Gene Ontology (GO) and Medical Subject
Headings Diseases (MeSH Diseases).
Drugs from
DrugBank
As far as the drug terms are concerned, CASSANDRA utilizes an in-
house dictionary of drugs derived from the DrugBank database (Wishart
et al., 2008). The DrugBank database is both a bioinformatics and chem-
informatics resource which combines detailed data descriptions and com-
prehensive target information for an extensive list of drugs. The database
currently contains over 7, 000 drug entries. Experimental drugs occupy
around 70% of the database. DrugBank also includes small molecule and
biotech (protein/peptide) drugs that are approved by the U.S. Food and
Drug Administration (FDA). Each drug record (DrugCard) contains more
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than 200 data fields with half of the information being devoted to drug/-
chemical data and the other half devoted to drug target or protein data
(enzymes, transporters, carriers).
Genes from
UniProtKB
Regarding the gene names, these are derived from UniProt Knowledgebase
(UniProtKB) 1. UniProtKB constitutes a central protein resource. It cap-
tures the core data of a protein (i.e., the amino acid sequence, protein name
or description, taxonomic data and citation information) and any annota-
tion information available, such as ontological terms, cross-references and
classifications. UniProtKB consists of UniProtKB/TrEMBL and UniPro-
tKB/SwissProt. The former contains unreviewed, automatically annotated
records. The latter, i.e., UniProtKB/SwissProt, contains manually curated
records and is utilized by CASSANDRA.
Gene Ontology
As far as the ontologies are concerned, GO 2 and MeSH 3 constitute the
terms that form the profiles and are used towards the characterization of
drugs and genes. GO is the major and freely available controlled vocab-
ulary of genes and gene products (Ashburner et al., 2000). GO explicitly
focuses on the unification of genes’s representation across all species (Con-
sortium, 2008). GO is a dynamic ontology that is maintained and enriched
regularly. It consists of three subontologies; Biological Process, Molecular
Function and Cellular Component. GO is structured as a Direct Acyclic
Graph, meaning a graph with no directed cycles. Each term has defined
relationships with other terms in GO.
MeSH
Medical Subject Headings (MeSH ) is a popular medical controlled vocab-
ulary thesaurus. It is freely available and maintained by the U.S. National
Library of Medicine (NLM ). MeSH consists of sets of terms (categories)
that are hierarchically structured. It is primarily used for indexing MED-
LINE articles and it is continually maintained. CASSANDRA focuses
on the Disease terms (descriptors) to characterize genes and drugs. Only
MeSH Disease terms found in text are used. MeSH terms provided by
MEDLINE are ignored so that CASSANDRA remains independent of
any manual annotation and hence generally applicable.
1http://www.uniprot.org/
2http://geneontology.org/
3http://www.nlm.nih.gov/mesh/
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3.1.2 Recognition of terms in text
The recognition of terms in text involves the identification of drug names
and their synonyms, gene names and GO and MeSH terms. The recogni-
tion of genes and drugs in biomedical text is analytically described in Plake
(2010). For the sake of coherence, the details of the annotation process are
once more explained.
Gene
annotation
Regarding the gene annotation process, GNAT was utilized (Hakenberg
et al., 2008a). GNAT is a publicly available system that handles inter-
species gene mention normalisation. Unlike traditional gene annotators,
GNAT uses background knowledge on genes to assign ambiguous gene
names to the correct Entrez Gene identifiers with a reported F - measure of
81.4% (90.8% precision at 73.8% recall). On the single species task consid-
ering only human genes, GNAT achieved an F -measure of 85.4%. Briefly,
gene annotation with GNAT is divided in four stages. First, it searches for
different species mentioned in text. Then, for all the species detected, dic-
tionaries are loaded and the names of genes are annotated. The third step
applies filters to remove false positive gene names, such as names of gene
families, diseases or names that are ambiguous with common English words
(e.g., white). In the last step of the gene annotation, the remaining candi-
date genes are ranked to the respective gene mention using context profiles
built from Entrez Gene and UniProt annotations. Figure 3.1 summarises
the key idea behind the gene mention normalisation with GNAT.
Drug
recognition
For the task at hand, an in-house drug dictionary was utilized (Plake,
2010). A list of drugs and their synonyms was drawn from DrugBank and
their identification in text is conducted with the use of regular expressions.
Each drug along with its synonyms is represented by a regular expres-
sion that captures its occurrence in text, taking into consideration slight
spelling or naming modifications, e.g., capitalization, different spellings of
their chemical IUPAC (International Union of Pure and Applied Chem-
istry) name 4. Table 3.1 provides some relevant examples. All regular
expressions are compiled to a single Labeled Deterministic Finite State Au-
tomaton (LDFA). Each end state in the automaton stores the corresponding
4http://www.iupac.org/
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Figure 3.1: Interspecies gene mention normalisation with GNAT
Gene p54 has a profile of four contexts. Only the first context from the left
reports the concepts Human, RNA helicase and q23.3 chromosomal band, which
are also found in text (from Hakenberg et al. (2008b)).
identifiers of all drug names that potentially end at this state. When pars-
ing a text, a match with the LDFA immediately triggers the annotation of
the matching phrase with all identifiers associated with the corresponding
accept state. To deal with the false positives that result from ambiguous
abbreviations (e.g., ACC for Acetylcysteine or Adenoid Cystic Carcinoma),
the abbreviations are mapped to their long forms with the use of the algo-
rithm introduced by Schwartz and Hearst (2003). To assess the efficacy of
this dictionary towards the implementation of CASSANDRA, a random
set of 60 MEDLINE records was generated out of the set of 22 million
references utilized by the suggested methodology. The corresponding titles
and abstracts were manually annotated. The respective dictionary achieves
a precision of 88% and a recall of 93% on the identification of drug names
from DrugBank.
MeSH and GO
terms
identification
As far as the recognition of MeSH Disease and GO terms in text is
concerned, this was made through the usage of GoPubMed (Doms and
Schroeder, 2005), a knowledge-based search engine that organizes MED-
LINE references with MeSH and GO annotations. GoPubMed exploits
the hierchical structure of the ontologies and their word composition. It
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Table 3.1: Drug representation with regular expressions - Examples
Drug Synonyms Representation
Fluocinonide
Fluocinonide
Fluocinonido \b(Ff)luocinonid\w+
Fluocinonidum
2-Phosphoglycolic Acid (II|2|ii)[ -]?[Pp]hosphoglycolic[ -]?[Aa]cid
The table shows how the regular expressions are formulated so as to catch both
synonyms and the official name of the drug.
first finds matching seed ontological terms in text and then, it iteratively
extends this set of terms to provide a full annotation for the respective
MEDLINE abstract (Delfs et al., 2004). Figure 3.2 demonstrates how an
abstract is annotated with GoPubMed. With respect toMeSH, only disease
terms were considered. On the other hand, GO was fully used.
3.1.3 Profile generation for drugs and genes
Following the recognition of drugs, genes and ontological terms in text, we
proceed with the automatic generation of context profiles for drugs and
genes. This is a step of particular importance, since the ontological profiles
constitute the means for the estimation of the relatedness between a drug
and a gene and hence, the establishment of putative drug gene associations.
As it has been already mentioned, the context profiles consist of ontological
terms derived from GO and MeSH. The context profiles are literature-
based, meaning that they rely on the ontological terms that co-occur with
drugs or genes in MEDLINE indexed abstracts and titles.
The profile generation for drugs (or genes) is divided in two separate steps;
• Quantification of the strength of the associations between drugs (or
genes) and ontological terms,
• Exclusion of probable incidental associations and generation of the
final context profiles for genes and drugs.
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Compute the
strength of
associations
Regarding the first step, the strength of each association between the
drug (or gene) and the respective ontological term is computed based on
the Pointwise Mutual Information (PMI ). PMI is a probabilistic measure
used to assess the strength of word collocations in a text corpus (Man-
ning and Schu¨tze, 1999). In corpus linguistics, a collocation is a sequence
of words that co-occur more often that it would be expected by chance.
Analogously to the collocation definition, we extent the application of PMI
to co-occurring pairs of drugs (genes) and ontological terms in MEDLINE
abstracts and titles. Thus, the higher the PMI score, the lower the proba-
bility that the drug (gene) and ontological term co-occur by chance.
Let E represent a drug or a gene entity term and C represent a MeSH
Disease or a GO term. We denote with nE the number of documents
where E occurs, nC the number of documents where C occurs, and nE,C
the number of documents where E and C co-occur. N denotes the number
of documents that any E is found to co-occur with any C. PMI between
any given E and C is then defined as shown in Equation 3.1. The higher
the PMI score of the two terms E and C is, the more probable it becomes
to observe these two terms together in the same document.
pmi(E,C) = log
N × nE,C
nE × nC (3.1)
However, the values that the PMI score can receive are not fragmented
and can rather take any real value. For this reason, we adopt the nor-
malised PMI (Bouma, 2009) (nPMI ) that takes values between [−1,+1].
Equation 3.2 shows the definition of nPMI given any two terms E and C.
If nPMI equals −1, this means that there is no co-occurrence between E
and C in the corpus. A negative value signifies that E and C co-occur less
frequently than one would expect by chance. Conversely, a positive value
indicates that the two terms co-occur more frequently than it would have
been expected by chance, and a value of 1 shows complete co-occurrence
between E and C. An nPMI score of 0.0 shows independence between E
and C, meaning that the two terms co-occur exactly as frequently as it
would have been expected by chance. For that reason, only associations
assigned an nPMI score greater than 0.0 were considered meaningful and
thus, the respective concepts C were included in the profiles of the entities
E.
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npmi(E,C) =
pmi(E,C)
− log nE,C
N
(3.2)
Associations
refinement
To enhance the quality of the automatically generated ontological profiles,
a further refinement of the terms that participate in a profile is applied.
Hence, an ontological term is included in the context profile of a drug (or
gene), if its nPMI score with the respective drug (gene) meets the following
requirements.
Let A represent the set of ontological terms C that co-occur with an entity
E. For all terms C that co-occur with the entity E, we compute the nPMI
score. Then, we calculate the arithmetic mean of the respective nPMI
distribution. We retain for the profile the terms C, where
npmi(E,C) ≥ meanA(npmi(E,C)) (3.3)
This step constitutes a refinement of the ontological terms inside the profile.
Besides this, an external refinement is applied with respect to the overall
distribution of nPMI scores between any drug (gene) and any ontological
term, where
p-value(npmi(E,C)) ≤ 0.05 (3.4)
npmi(E,C) ≥ mean(npmi(E,C)) (3.5)
among all the npmi(E,C) scores between any entity E and any concept C.
Analytically, all the ontological terms which participate in a context profile,
must have a statistically significant nPMI score with the respective drug
or gene. Additionally, the nPMI score between a drug (or a gene) and an
ontological term must be greater than the arithmetic mean of the nPMI
scores distribution between any drug (or gene) and any ontological term.
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3.1.4 Computation of semantic relatedness between
the profiles
After having generated the context profiles for all drugs and genes found
in MEDLINE abstracts and titles, in this step, the relatedness between
drugs and genes is computed based on their profiles. Unlike the previous
step, wherein PMI qualified the selection of the ontological terms that will
participate in a profile, herein, the respective formula is used to estimate
the statistical semantic similarity between a drug and a gene based on their
context profiles.
MeSH Disease,
GO and joined
profile
similarity
An ontological profile can be viewed either as a consolidated set of ontolog-
ical terms from both GO and MeSH Disease, or as a set of two individual
subprofiles, each one including terms from one single ontology. To compute
the relatedness between a drug and a gene profile, three scores of statistical
semantic similarity are calculated and then combined into an overall score;
one score corresponds to the similarity between the MeSH Disease profiles,
one score corresponds to the similarity between the GO profiles and the
third score corresponds to the similarity between the consolidated profiles
that consist of both types of ontological terms.
Given one type of ontological profile, meaning MeSH Disease, GO or a
consolidated profile, the computation of the relatedness between a drug
and a gene is based on the nPMI values between all possible pairs of the
ontological terms comprising the drug and gene profiles. Thus, for each
drug-gene pair all the possible combinations between their profile terms
are generated and the nPMI score for each such combination is computed.
The computation is based on Equation 3.2.
More formally, let Pd the set of the profile terms for a drug d and Pg the set
of the profile terms for a gene g. For every term pair (Cd ∈ Pd, Cg ∈ Pg),
the npmi(Cd, Cg) is computed as shown in Equation 3.2.
Subprofile
similarity
Once all of the npmi(Cd, Cg) scores between all possible pairs of the drug
and the gene profile terms are computed, the scores are combined to pro-
duce the overall score between the drug and the gene. We compute the
combination of scores following the methodology described in the work of
Varlamis et al. (2004). The proposed measure has been used in the past
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to estimate the similarity between two sets of ontological terms (Halkidi
et al., 2003).
In detail, given Pd and Pg the drug and gene profile terms respectively, for
each Cd ∈ Pd the maximum npmi(Cd, Cg) score is detected, and the average
of all such maximum scores is computed. This is shown in Equation 3.6 as
S1(d, g).
S1(d, g) =
1
|Pd|

Cd∈Pd
max
Cg∈Pg
npmi(Cd, Cg) (3.6)
Similarly, S2(g, d) is computed for all Cg ∈ Pg, the way it is shown in
Equation 3.7.
S2(g, d) =
1
|Pg|

Cg∈Pg
max
Cd∈Pd
npmi(Cg, Cd) (3.7)
Finally, the two scores S1(d, g) and S2(g, d) are combined as shown in Equa-
tion 3.8 to produce the overall score between a drug d and a gene g.
Score(d, g) =
1
2
(S1(d, g), S2(g, d)) (3.8)
Hence, to estimate the semantic relatedness between a drug and a gene,
each ontological term from the drug’s profile is paired with the ontological
term from the gene’s profile which gives the highest nPMI score. At the
end, only the combinations of terms that produce the highest scoring pairs
are kept.
Overall score
computation
After computing the semantic relatedness for each type of subprofiles, the
overall score of semantic relatedness between a drug d and a gene g, i.e.,
SemRel(d, g), is calculated as follows:
SemRel(d, g) =1−
[(1− Score(d, g)go) ∗ (1− Score(d, g)ds)∗(1− Score(d, g)go,ds)]
(3.9)
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where Score(d, g)go, Score(d, g)ds and Score(d, g)go,ds is the semantic relat-
edness between the GO, MeSH Disease and consolidated profiles of a drug
d and a gene g respectively.
The computation of the overall score is based on the Noisy-OR gate model.
This distribution belongs to the family of models which is often referred
to as Independence of Causal Influences (ICI ). It is used when there are
several possible causes for an event, any of which can cause the event by
itself with a certain probability (Zagorecki and Druzdzel, 2004). Corre-
spondingly, each subprofile similarity score is viewed as a probability score
that independently can cause the event of similarity between a drug and a
gene.
Given a collection of drug-gene pairs, the suggested methodology assigns
a score to every drug-gene pair. These pairs are then, in turn, ranked to
suggest putative drug-gene associations. The higher the score is, the higher
the semantic relatedness between the respective drug and gene.
3.2 Materials and Methods - Evaluation
3.2.1 Evaluation datasets
In the current section, the datasets utilized for the evaluation of the algo-
rithm’s efficacy are analysed. The datasets serve two different evaluation
purposes:
• drug gene association prediction and,
• drug repositioning.
3.2.1.1 Evaluation datasets for drug gene association prediction
For the evaluation of the proposed algorithm towards drug gene association
prediction, a series of datasets is necessary. The datasets should consist of
true and false drug gene associations. The suggested algorithm assigns a
semantic relatedness score to every drug-gene pair included in the dataset.
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Once the scores are assigned, the drug-gene pairs are ranked and the per-
formance of the algorithm is evaluated based on the prioritization of true
over false drug gene associations.
Two
evaluation
aspects -
(1)Profile type
(2)Semantic
similarity
metric
In the current work, the performance of the algorithm is examined based on
two main aspects of evaluation. One aspect pertains to the type of drug and
gene profiles, and another one pertains to the computation of their semantic
relatedness. The former involves the potential of the proposed methodology
to utilize either co-occurrence based profiles retrieved from the biomedical
literature or manually curated profiles. The question that arises is what is
the impact of each profile type in the algorithm’s performance. The latter
involves the comparison of nPMI against traditional measures of semantic
similarity. Is nPMI indeed the most efficient measure of semantic similarity
for the task at hand? Both tasks account for the use of datasets that allow
the efficient demonstration of the algorithms’s performance differentiations.
Resources
Few
benchmark
datasets
Obtaining datasets of drug gene associations is a rather demanding task
due to their limited number. Notably, there exists only one Gold Standard
set of drug target interactions which was introduced in the work of Ya-
manishi et al. (2008). In this work, the authors formalized the drug target
interaction inference as a supervised learning problem by combining chem-
ical structure and genomic sequence information. For the evaluation of
their approach, they characterised four classes of drug target interactions
in humans involving enzymes, ion channels, G-protein-coupled receptors
(GPCRs) and nuclear receptors. Then, they utilized that information to
examine the performance of their methodology towards the prediction of
drug target interactions. Their dataset has been, since then, extensively
used as a benchmark by several supervised methodologies towards drug
target interaction prediction (Pahikkala et al., 2014). In the current work,
this dataset is also included in the performance evaluation of the proposed
algorithm and we shall refer to it as the Yamanishi dataset.
DrugBank
dataset
To expand the evaluation of the suggested methodology, the absence of
benchmark drug gene associations sets has to be tackled. On that ac-
count, a series of additional datasets are compiled based on sets of true
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drug gene associations available in public pharmacogenomic databases. For
that purpose, two popular drug related repositories were considered; Drug-
Bank and the Comparative Toxicogenomics Database (CTD) (Davis et al.,
2012). Both databases constitute freely accessible repositories of high-
quality pharmacological data. As it has been mentioned before, DrugBank
is both a bioinformatics and cheminformatics resource which combines de-
tailed data descriptions and comprehensive target information for an exten-
sive list of drugs. The fact that the dictionary used during the annotation of
drugs in MEDLINE titles and abstracts was built based on this database,
makes DrugBank ’s drug target information ideal for the generation of a
benchmark dataset.
CTD dataset -
manually
curated profiles
test
CTD, on the other hand, takes one step further and, unlike traditional
drug-related repositories which comprise mainly structural and chemical
information of drugs along with a list of their physically binding targets, it
includes formalised associations between drugs, genes and diseases. These
associations are either curated or inferred. Notably, the curated associa-
tions are derived from MEDLINE articles and the respective textual ev-
idence is also included in the database. Each set of diseases which are
reported to be associated with either a drug or a gene in CTD can be
considered as a manually curated profile that characterises the respective
drug (or gene). This makes CTD an ideal candidate for the generation of
a benchmark dataset on which the performance of the algorithm can be
analysed when manually curated profiles are used. Most importantly, the
intersection of drug gene associations provided by the suggested method-
ology and CTD form an additional dataset which enables the performance
comparison of the co-occurrence based profiles against the manually cu-
rated profiles.
Compilation of datasets
The compilation of the datasets is conducted as described in Figure 3.3.
The datasets are compiled similarly to the so far unique benchmark dataset
provided by Yamanishi et al. (2008). Indicatively, for each of the sets
there exist both true and false examples of drug-gene interactions. The
first step is to extract the positive pairs (true interactions) listed in each
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Figure 3.3: Drug gene association datasets compilation
The pipeline for the compilation of the datasets used to evaluate CASSANDRA
is shown. The set of true drug gene associations is retrieved from each resource.
All drugs and genes are combined to generate the false drug gene pairs set.
Then, all drug gene pairs wherein the drug and the gene co-occur in at least
one MEDLINE reference are removed. Lastly, all drug gene pairs containing a
non-profiled drug or gene are also excluded from each dataset.
database. These pairs are then, in turn, used for the generation of the
negative examples (false interactions).
Unknown non-
interacting
drug-gene
pairs
More precisely, each drug is paired with every gene and the resulting
pairwise combinations constitute the so-called false drug gene associations.
These associations are considered false based on the fact that they are not
reported by the respective pharmacogenomic resource, although in actual
fact they may as well constitute true drug gene associations, which have not
yet been confirmed experimentally. However, since there is no information
regarding non-interacting drug targets the above convention is necessary
for the compilation of the evaluation datasets. Still, any false drug gene
association scored highly by the proposed algorithm constitutes an in-silico
prediction of a putative drug target interaction.
Positive bias
of co-occurring
drugs and
genes
Two additional steps follow the generation of false drug gene associations.
The former is to exclude from the evaluation dataset all these drug gene
pairs for which there is at least one co-occurrence in a MEDLINE abstract
or title. This is due to the fact that the goal of this study is to present
a methodology that is able to indirectly pinpoint the similarity between
a drug and a gene. On the premise that their co-occurrence is itself a
signal of putative relation, these drug gene pairs are excluded, even in the
case their nPMI score is negative. Indeed, including drug gene pairs of co-
occurring drugs and genes in the evaluation is shown to introduce a positive
bias in the algorithm’s performance and hence, conceal the algorithm’s true
efficacy (see Chapter 4, Section 4.3.1.1).
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Positive bias
of non-profiled
drugs and
genes
Given the fact that not all drugs (genes) have profiles generated, the final
step is to exclude from the datasets the drug gene pairs wherein either the
drug or the gene has an empty profile. Two are the reasons for which a
drug or a gene is assigned an empty profile; either the annotators reported
no occurrence of the respective entity in MEDLINE abstracts and titles,
or the ontological terms occurring with the entity do not participate in the
profile due to their unfitting nPMI score as this has been defined in Section
3.1.3. Pairs of empty profiles result in zero scored drug gene associations
that when included in the evaluation falsely enhance the performance of the
suggested algorithm. Markedly, such is the case of the DrugBank dataset;
41 % of the false drug gene pairs generated after the exclusion of non-co-
occurring drugs and genes, consist of non-profiled entities. When scored
with zero, these pairs boost the performance of the suggested algorithm but,
on the other hand, they obfuscate its true discriminative power. Excluding
them eliminates the bias that they introduce (see Table 4.6).
3.2.1.2 Evaluation sets for drug repositioning
No available
drug
repositioning
dataset
Towards demonstrating the application of the method in identifying can-
didate drug repositioning cases, a set of all known drugs that have been
repositioned has to be compiled. Ideally, the set should include along with
the drug identifiers, the old indication of each drug and the new indication.
However, there is no such dataset publicly available. Drug repositioning
cases are scattered across the literature. For that reason, the literature
is systematically mined for the manual generation of a dataset comprising
drug repositioning data. The set includes drugs for which there exists a
DrugBank identifier. Apart from MEDLINE abstracts, information is ex-
tracted from the FDA, Wikipedia and other web resources comprising drug
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related data 5. Old and new indications are reported along with the year
of approval of each drug’s new indication.
For the task at hand, we focus on drugs that were FDA approved within
the last 5 years with their new indications and for which the proposed
algorithm has generated co-occurrence based profiles out of biomedical lit-
erature. Thus, allMEDLINE data from 2009 and on was excluded from the
application of the suggested methodology. The application of the method
in identifying candidate drug repositioning cases is conducted as follows:
the drug’s profile is generated, and the MeSH disease terms that partic-
ipate in the profile are examined. The efficacy of the approach can then
be assessed on whether the new indication is included in the drug’s profile,
and if so, whether it is ranked high in the list of the drug’s profile terms.
3.2.2 Alternative semantic similarity metrics
CASSANDRA utilizes the statistical measure nPMI to quantify the se-
mantic similarity between a drug and a gene profile. To assess the nPMI ’s
efficacy, the suggested measure is compared with two traditional metrics of
semantic similarity; the Wu-Palmer (1994) and Lin (1998) measures.
Wu and Palmer
For two concepts C1 and C2 and their LCA Least Common Ancestor C3,
the Wu-Palmer semantic similarity is defined as follows:
5
http://www.cancer.gov/
http://www.centerwatch.com/
http://www.drugs.com
http://www.medicalnewstoday.com/
http://www.medscape.com/
http://www.webmd.com/
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WP (C1, C2) =
2× depth(C3)
2× depth(C3) + distance(C1, C3) + distance(C2, C3)
(3.10)
, where depth(C3) = distance(C3, root)
For two ontological concepts, the Wu-Palmer metric estimates their se-
mantic relatedness by calculating the distance of the shortest path that
connects them in the ontology. The lower the distance between the con-
cepts and their LCA and the higher the distance of LCA from the root of
the ontology, the greater the similarity of these concepts.
Lin
Let two concepts C1 and C2 and their LCA Least Common Ancestor C3.
The Information Content of C1 is defined as:
IC(C1) = − logP (C1) (3.11)
, where P (C1) is the probability of occurrence of the concept C1 in the
corpus. The higher the probability of a concept’s occurrence, the lower the
IC of the concept is.
The Lin semantic similarity is, then, calculated as follows:
Lin(C1, C2) =
1
IC(C1) + IC(C2)− 2× IC(C3) (3.12)
As shown by the equation above, the Lin metric takes into account the
hierarchy of the ontology, but also considers the Information Content (IC )
of the concepts in the calculation of semantic relatedness. Thus, it is both
a probabilistic and structural metric of semantic similarity.
Chapter 4
Results
This Chapter describes the tasks that were conducted to evaluate the effi-
ciency of CASSANDRA towards drug gene association prediction. More
specifically, this chapter reports
• The occurrence and co-occurrence statistics of terms in abstracts and
titles of MEDLINE indexed articles.
• The statistics of the drug gene association datasets used for the al-
gorithm’s evaluation.
• Analysis of the algorithm’s performance towards drug gene associa-
tion prediction.
– How does the type of ontological profiles affect the algorithm’s
prediction efficacy? Are manually curated profiles better than
co-occurrence based profiles?
– Is nPMI the most appropriate measure of semantic similarity?
• Analysis of the algorithm’s performance towards drug repurposing.
Do the profiles include the new indications?
• Manual analysis of three drug gene associations proposed by CAS-
SANDRA.
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4.1 MEDLINE statistics
Overall, 23, 487, 871 MEDLINE abstracts and titles that were available
at the time of the algorithm’s implementation are considered. Table 4.1
shows the number of unique drugs, genes, MeSH Diseases and GO terms
found in these MEDLINE abstracts and titles. Additionally, the table
shows the number of documents that contain at least one term of interest.
Notably, the numbers reported indicate the excess of information available
in MEDLINE abstracts and titles and motivates the exploitation of the
respective data.
Table 4.1: Statistics of term annotations in MEDLINE
Term Number Documents
drug 2, 909 4, 599, 847
gene 58, 261 3, 512, 899
Gene Ontology
Biological Process 8, 602, 996
20, 255 Molecular Function 4, 550, 929
Cellular Component 3, 036, 912
MeSH Disease 4, 194 13, 242, 432
Table shows the considered term types, along with the number of the unique
terms recognised. The final column shows the number of the MEDLINE titles
and abstracts containing at least one annotation of the respective term type. Ev-
idently, the number of terms and documents indicates the excessive information
available.
The same holds for the co-occurrences of drugs and genes with MeSH Dis-
eases and GO terms. As shown in Table 4.2, the co-occurrences are plenti-
ful and hence they can be used for the contextual description of drugs and
genes. In particular, the vast majority of drugs and genes co-occur with up
to 100MeSH Disease and 300 GO terms (∼ 100 terms of each subontology)
(see Figure 4.1). Limited are the drugs and genes that co-occur with more
than 1000 terms. Evidently, the necessity to quantify the strength of each
co-occurrence rises. Not every MeSH Disease or GO term co-occurring
with either a drug or a gene can be included in the respective profile, and
thus this motivates the use of nPMI. As it has been mentioned in Section
3.1.3, the higher the nPMI score, the lower the probability that a drug (or
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gene) and an ontological term co-occur by chance. The additional filtering
steps enhance the quality of the profiles.
Table 4.2: Co-occurrences for drugs, genes and ontological terms in
MEDLINE
Entity Ontological Term Documents
drug MeSH Disease 2, 828, 259
GO biological process 2, 644, 296
GO molecular function 1, 747, 743
GO cellular component 1, 001, 228
gene MeSH Disease 2, 360, 673
GO biological process 2, 439, 335
GO molecular function 2, 030, 772
GO cellular component 1, 121, 913
The table shows the number of MEDLINE abstracts containing at least one
co-occurrence of a drug or a gene with a MeSH disease or a GO term.
The co-occurrences between ontological terms in MEDLINE abstracts are
also quantified. The results are shown in Table 4.3. Evidently, the number
of documents containing at least one co-occurrence of two distinct MeSH
Disease or GO concepts is significantly large. This suggests that nPMI
can be used as a measure of semantic similarity between two ontological
terms.
Table 4.3: Ontological terms co-occurrences in MEDLINE
Ontological Term Ontological Term Documents
MeSH Disease MeSH disease 9, 065, 044
Gene Ontology Gene Ontology 6, 885, 166
MeSH Disease Gene Ontology 6, 320, 168
MEDLINE abstracts and titles containing at least one co-occurrence between
two MeSH Disease or GO concepts. The number of co-occurrences is signif-
icantly large and this motivates the use of nPMI as a measure of semantic
similarity between the ontological terms.
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Figure 4.1: Graphical representation of co-occurrences for drugs and
genes
The vast majority of drugs and genes co-occur with up to 100MeSH Disease and
300 Gene Ontology terms (∼ 100 terms of each subontology). Limited are the
drugs and genes that co-occur with more than 1000 terms. Notably, not every
term can be included in a drug/gene profile. The strength of co-occurrences has
to be quantified and the meaningless co-occurrences have to be excluded.
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4.2 Evaluation datasets statistics
In this subsection, the statistics of the datasets used for the evaluation
of the algorithm’s performance are provided. The resources and compi-
lation pipeline utilized for the generation of the evaluation datasets are
analytically described in Section 3.2.1.1. Table 4.4 gives an overview of the
resulting datasets and reports the number of drugs, genes and associations
(true and false) per dataset. It also reports the evaluation aspect for which
each dataset is considered.
Approved &
Experimental
The DrugBank dataset splits in two subsets; the Approved and the Exper-
imental. The former includes drugs that have been already approved and
entered the pharmaceutical market, whilst the latter includes experimental
compounds. The discrimination between these two datasets demonstrates
whether the type of a drug affects the performance of the suggested al-
gorithm or not. The datasets DrugBankApproved , DrugBankExperimental and
Yamanishi are used for the evaluation of the proposed methodology when
co-occurrence based profiles are considered.
Binding &
Related
Analogously, the CTDBinding and CTDRelated sets are used to demonstrate
the potential of the suggested methodology to propose drug gene associa-
tions when manually curated profiles are considered. As shown in Table 4.4
CTD also splits in two subsets. This is due to the content of the database
itself. CTD includes two types of associations between drugs and genes;
the associations wherein the drug physically binds to a product of the re-
spective gene and the associations wherein the drug affects the regulatory
processes of a gene or one of its products. Hence, the CTD datasets are
accordingly compiled and form the Binding and the Related subsets respec-
tively. In the case of CTD, the drugs are stored in the repository with their
MeSH identifier from the MeSH tree Chemicals and Drugs. Seeing that
not all MeSH identifiers correspond to DrugBank identifiers and, hence,
mapping them would result to the loss of drug gene associations provided
by CTD, the CTD identifiers are retained.
The
comparison
dataset
Finally, the CTDcb&mc set is the intersection between the drug gene as-
sociations that have been identified and scored by the suggested algorithm
in MEDLINE abstracts and titles and the drug gene associations provided
by CTD. Consequently, all drug gene associations included in CTDcb&mc
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consist of drugs and genes that they have been assigned both manually
curated profiles by the CTD curators and co-occurrence based profiles by
the proposed algorithm. To compile this dataset, for all CTD drug gene
associations the drugs were, this time, mapped to their DrugBank identi-
fiers. The resulting drug gene associations were then compared with the
drug gene associations generated by the suggested algorithm after travers-
ing the literature and then, the intersection of these sets was retained. This
dataset is of particular importance as it enables the comparison between
co-occurrence based profiles that are derived from literature and manually
curated profiles. The subscript cb&mc stands for the Co-occurrence Based
& Manually Curated and helps to discriminate CTDcb&mc from the rest of
the datasets derived from CTD.
Figure 4.2: True drug gene associations Venn Diagram
An overview of the datasets used for the different evaluation aspects of the
suggested methodology. The Venn Diagram illustrates the overlap between the
true drug gene associations included in the three datasets. The significantly
small overlap indicates that the datasets are substantially differentiated.
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Differentiated
datasets
Figures 4.2 and 4.3 illustrate an overview of the datasets used for the
evaluation. The Venn Diagrams show the overlap between the DrugBank,
Yamanishi and CTDcb&mc datasets. As shown in Figure 4.2 the datasets
are significantly differentianted in terms of the true drug gene associations
they comprise. Indeed, all three of them have an overlap of only 27 drug
gene associations. They also differ in size. The explanation for that is
straightforward. The vast majority of drug gene associations in CTDcb&mc
are rather related than directly binding associations. On the other hand,
the DrugBank and Yamanishi sets contain drug gene associations where
the drug is proven to interact with the protein coded by the respective gene.
Figure 4.3 shows the overlap of the datasets it terms of drugs and genes. As
shown, the overlap in this case is again relatively small and the size of the
sets again varies. The high differentiation degree of the datasets poses two
advantages; first, it allows the comprehensive comparison of the suggested
algorithm with alternative implementations of the same methodology and
second, it demonstrates the robustness of the algorithms when inferring
putative drug gene associations.
Figure 4.3: Venn Diagrams for drugs and genes in the evaluation
datasets
An overview of the datasets used for the different evaluation aspects of the
suggested methodology. The drug and gene Venn Diagrams illustrate the overlap
between the three datasets with respect to the drugs and genes they include.
Similarly to the Venn Diagram of true drug gene associations, the datasets show
a substantial differentiation.
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4.3 Drug gene association prediction
In this section, the results of the algorithm’s efficacy towards drug gene
association prediction are reported. As it has been mentioned before, the
presented method utilizes the co-occurrences of GO and MeSH Disease
concepts with drugs and genes in MEDLINE titles and abstracts. Based
on that co-occurrence information, profiles of ontological terms are created
for both drugs and genes. Then, with the help of a corpus-based statistical
measure, nPMI, the drugs are associated to genes by assessing the semantic
relatedness of their profiles. Then the proposed drug gene associations are
prioritized based on their relatedness score. For details regarding the steps
of the algorithm, please refer to Chapter 2 (Background).
The suggested algorithm was applied on a series of evaluation datasets (for
details regarding the datasets compilation and statistics, please refer to
Sections 3.2.1.1 and 4.2 respectively). As shown, the datasets consist of
true and false drug gene pairs. The proposed algorithm assigns a score
of semantic relatedness to every drug gene pair included in these datasets
and the drug gene pairs are, afterwards, ranked according to that score. To
demonstrate the algorithm’s efficacy towards the prioritization of true drug
gene associations, the respective Receiver Operating Characteristic (ROC )
curves, Area Under the Curve (AUC ) values and Precision-Recall (PR)
curves are provided.
ROC curves
ROC curves have been extensively used towards the evaluation of binary
decision algorithms (Bandos et al., 2010). In a binary decision problem, the
classifier labels input examples as either positive or negative. A ROC curve
plots the True Positive Rate (TPR) on the x -axis and the False Positive
Rate (FPR) on the y-axis for different cut-off points. Each point on the
ROC curve, meaning a TPR-FPR pair represents the fraction of positive
examples that have been correctly labeled with respect to the fraction of
negative examples that are misclassified as positive, corresponding to a
particular decision threshold. An algorithm with no overlap between the
two distributions, hence with a TPR of 1.0 and a FPR of 0.0, succeeds a
perfect discrimination between the class of the positive and the class of the
negative examples. Therefore, the closer the ROC curve is to the upper
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left corner, the higher the overall accuracy of the algorithm (Zweig and
Campbell, 1993).
AUC values
To evaluate the performance of the proposed method, in tandem with
the ROC curves, the respective Area Under the Curve (AUC ) values are
provided. The AUC of a classifier is basically the probability that the clas-
sifier will rank a randomly chosen positive instance higher than a randomly
chosen negative instance (Fawcett, 2006). In this work, ROC curves and
AUC scores are used in the notion of the performance evaluation applied in
the field of Information Retrieval (Manning et al., 2008). More precisely,
the usage of ROC curves illustrates the ability of the method to prioritize
the positive over the negative examples, having as an input only a ranked
list of examples. Herein, these examples are simply the scored drug gene
associations that correspond to each evaluation dataset. Given a particular
dataset, the probability of a randomly chosen positive drug gene associa-
tion to rank higher that a randomly chosen negative drug gene association
is represented by the corresponding AUC value.
PR curves
contribution
Besides ROC curves which are very insightful performance representations
in the case of binary classifications, PR curves are also utilized to illustrate
the efficacy of the algorithm. Unlike ROC curves , PR curves show the ratio
of true positives among all the predicted positives under a given recall rate.
It has been shown that a classification method dominates the ROC space
if and only if it dominates the PR space (Davis and Goadrich, 2006). PR
curves are particularly informative and biologically meaningful in the case
of imbalanced datasets (Chen et al., 2012). In an effort to give an overall
picture of CASSANDRA’s efficacy, the PR curves in varying degrees of
imbalance between true and false examples (i.e., 1:1, 1:2, 1:4 and 1:8) are
also provided.
Another insightful performance metric is Specificity (or True Negative Rate)
which measures the proportion of negatives that are correctly identified as
such. Apparently, to measure Specificity, a clear indication of what a true
negative example is becomes necessary. However, in the current evaluation
the datasets contain clear signals of what are the positive examples, but
it is not possible to accurately assess which are the true negative exam-
ples (and hence compute the Specificity) due to the absence of supporting
experimental evidence (as shown in Figure 3.3, the false examples were
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generated from the pairwise combination of all drugs and genes included in
the respective drug related repositories). The computation of Specificity re-
mains an open problem in the studies of drug-target prediction (Pahikkala
et al., 2014).
Two main
evaluation
parts
The evaluation of the algorithm towards drug gene association prediction
is divided in two main parts; the first part examines the performance of
the algorithm with respect to the type of terms that constitute the drug
and gene profiles. Both manually curated and co-occurrence based profiles
are utilized and the respective ROC curves, AUC values and PR curves
are provided. In the second part, alternative measures of semantic similar-
ity are explored and compared to the statistical semantic similarity metric
nPMI. Along with the ROC curves, AUC values and PR curves, the dis-
criminative power of each measure is also considered to assess in what
degree the positive drug gene associations differentiate from the negative
drug gene associations.
4.3.1 Performance evaluation - Ontological profiles
As it has been mentioned before, the proposed methology utilizes ontolog-
ical profiles in order to assess the semantic similarity between a drug and a
gene. The ontological profiles constitute the literature fingerprints of drugs
and genes, hence assessing their quality is of primary importance towards
the establishment of drug gene association predictions. In this part of the
evaluation, the role of ontological profiles is thoroughly examined.
In principle, the suggested algorithm utilizes co-occurrence based profiles
derived from biomedical literature. However, one main advantage of the
proposed pipeline is that it can also compute the semantic relatedness be-
tween a drug and a gene in case the respective manually curated profiles
are available. Consequently, the arising question is: Which profile type is
the most suitable in terms of the algorithm’s performance?
Thus, three evaluation aspects are considered for this task:
• Performance evaluation when co-occurrence based profiles are used.
• Performance evaluation when manually curated profiles are used.
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• Comparison of performance between manually curated and co-occurrence
based profiles.
4.3.1.1 Co-occurrence based profiles
With regards to this evaluation part, the DrugBank and the Yamanishi
dataset are utilized. Figure 4.4 demonstrates the performance of the algo-
rithm. The suggested method obtained an AUC of 0.84 for the DrugBank
drug gene associations in which Approved drugs participate and 0.58 when
Experimental drugs participate. Considering the reported results for the
Yamanishi dataset (an AUC of 0.74 was obtained), and taking into ac-
count its small overlap with the DrugBank datasets (as shown in Figure
4.2, the DrugBank and the Yamanishi datasets overlap only by 6% in terms
of true drug gene associations), the value of the AUC (0.74) suggests the
robustness of the suggested methodology.
Why better
performance
for Approved
drugs?
As it is demonstrated in Figure 4.4, the reported results suggest that the
AUC for the Approved drugs is higher than the AUC for the Experimental
drugs. To understand the reason for this difference, the number of litera-
ture references for both types of drugs is examined. Approximately, 87%
of the papers with at least one drug occurrence mention an Approved drug,
while only 25% of the papers mention an Experimental drug. The under-
epresentation of Experimental drugs in literature results in poor profiles
for the respective type of drugs. Indeed, the average number of concepts
in the profile of an Experimental drug is 273, while for an Approved drug
is 699 (see Table 4.5).
Why better
performance
for Human
genes?
Accordingly, when drug gene associations wherein Human genes partici-
pate are considered, the AUC values increase for both Approved and Exper-
imental drugs to 0.88 and 0.77 respectively, as shown in Figure 4.5. This is
because, Human genes are discussed more in literature than the genes that
belong to other species. Altogether, genes from 31 species were annotated
in MEDLINE abstracts and titles. Approximately, 70% of the papers with
at least only one gene occurrence mention a Human gene, while 38% of
the papers mention genes that belong to the rest of 30 other species. The
average number of concepts in the profile of a Human gene is 451 and it is
significantly higher than that of a gene which belongs to other species (i.e.,
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Figure 4.4: ROC curves for co-occurrence based profiles
ROC curves for datasets when co-occurrence based profiles are utilized. The
curves show that CASSANDRA is robust and predicts well if there is sufficient
underlying data (Approved and Yamanishi). For Experimental drugs little is
published and hence the method performs worse.
61). This explains the improvement in the performance of the proposed
algorithm when applied on the respective subset.
The above results suggest that the method under evaluation successfully
interrelates drugs and genes even when these are not co-mentioned in text.
Clearly, the amount of literature references plays a significant role towards
the establishment of reliable profiles for both drugs and genes and the
computation of their semantic relatedness.
The impact of empty-profiled and co-occurring entities
At this point, two important steps towards the assessment of the algo-
rithm’s efficacy have to be pinpointed; the exclusion from the evaluation
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Table 4.5: Arithmetic mean of statistically significant concepts in pro-
files
Entity Type Disease GO All Documents (%)
drug Approved 239 461 699 87
Experimental 58 215 272 25
gene Human 161 290 451 70
non-Human 17 44 61 38
The table reports the average number of statistically significant concepts that
are included in the profiles of Approved/Experimental drugs and Human/non-
Human genes. The percentage of documents that include at least one occurrence
of the each entity are also provided. The underpresentation of the Experimental
drugs and non-Human genes in literature results in poor profiles. This affects
the algorithm’s performance on the respective datasets.
datasets of drug gene pairs that constitute by a drug or a gene with an
empty profile and the exclusion of drug gene pairs wherein the drug is
found to occur with the gene in at least one MEDLINE publication (see
Figure 3.3). These steps have a significant impact in the demonstration of
the algorithm’s performance.
The impact of
empty-profiled
entities
More specifically, when drugs and genes with an empty profile are consid-
ered, the AUC values obtained for the datasets DrugBankApproved , Drug-
BankExperimental and Yamanishi are 0.89, 0.50 and 0.74 respectively. This
effect can be explained when considering the statistics reported in Table
4.6. When a drug gene pair constitutes of an empty-profiled entity, the
association score between the drug and the gene equals to 0.0. Thus, the
inclusion of such pairs in the evaluation datasets signifies the increase in
the number of zero-scored drug gene pairs.
The better get
better
As shown in the Table, 41% of the initial set of false drug gene associations
consist of an empty-profiled drug or gene, hence 41% of the drug gene pairs
have an association score of 0.0. On the other hand, the majority of the true
drug gene pairs included in the DrugBankApproved dataset are scored highly
(see upper left corner of Figure 4.12). Consequently, the classification task
in this case is facilitated and the algorithm obtains an AUC of 0.89 (instead
of the previously reported 0.84).
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Figure 4.5: ROC curves for Human and non-Human genes
Performance evaluation of associations between drugs and Human genes. The
curves show that CASSANDRA performs better when drug gene pairs include
Human genes. For Human genes there is a lot published and that has a beneficial
impact on the method’s performance.
The worse get
worse
However, the situation differs for the dataset that consists of Experimental
drugs. The percentage of empty profiled pairs for both true and false drug
gene associations is similar (46% and 41% respectively). At this point, it
has to be noted that the score distributions between the true and the false
drug gene associations contained in this dataset are already quite similar
(see 1st row, 2nd column in Figure 4.12). When considering the empty-
profiled pairs in the evaluation, the distributions become even more alike
and this results in the drop of the algorithm’s classification performance.
The AUC obtained is 0.50 (i.e., random classification). On the other hand,
the performance of the algorithm in the Yamanishi dataset remains stable
to an AUC of 0.74. This is no surprise, if we take into account that less
than 1.0% of the drug gene pairs constituting both the initial set of true
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Table 4.6: AUC values when including non-profiled drugs and genes
% empty-profiled AUC
true pairs false pairs
DrugBankApproved 0.01 41
0.89
DrugBankExperimental 46 0.50
Yamanishi 0.02 0.4 0.74
The table reports the percentage of empty-profiled drug gene pairs contained in
the initial evaluation datasets and the respective AUC values. For the Drug-
BankApproved dataset, the performance improves due to the high association score
of true drug gene pairs and the high percentage of empty-profiled false drug gene
pairs. In the DrugBankExperimental dataset, true and false drug gene pairs con-
tain similar percentages of empty-profiled drug gene pairs, hence, the AUC value
drops to 0.50. In the Yamanishi dataset the small amount of empty profiled drug
gene pairs hardly affects the classification task.
and false drug gene pairs of the Yamanishi dataset consist of empty profiled
drug gene pairs.
The impact of
co-occurring
entities
Similar is the case when the evaluation datasets include drug gene pairs
that consist of drugs and genes which co-occur in at least one MEDLINE
record. For example, in the case of the DrugBankApproved dataset, such
pairs further boost the algorithm’s performance by 4.0% (this time the
algorithm obtains an AUC value of 0.91). However, the goal of this study
is to present a methodology that is able to indirectly pinpoint the similarity
between a drug and a gene.
Consequently, to elucidate CASSANDRA’s true classification efficacy, the
drug gene pairs that consist of empty-profiled or co-occurring drugs and
genes are excluded from the evaluation datasets. This way the method
remains free from positive bias that would render the proposed drug gene
association prediction method overoptimistic.
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4.3.1.2 Manually curated profiles
The suggested algorithm utilizes co-occurrence based profiles of ontological
concepts derived from the biomedical literature towards the assessement of
latent associations between drugs and genes. These profiles can be viewed
as feature vectors for drugs and genes. The methodology can incorporate
any such feature vectors as long as they consist of MeSH Disease and GO
terms. Ideal is the case of acquiring a set of manually curated ontological
terms that are found and suggested by curators to be associated with a drug
or a gene. On that premise, couldCASSANDRA successfully predict drug
gene associations? To answer this question, CTD is utilized.
Why CTD?
As it has been aforementioned, CTD is a publicly available biomedical
repository, which unlike to other resources that comprise pharmacological
information, it also contains formalized relations between drugs, diseases
and genes. These relations are being manually curated in a regular basis,
so that CTD constitutes a reliable and up-to-date pharmacological reposi-
tory. For this evaluation step, the drug-MeSH Disease and the gene-MeSH
Disease relations provided by CTD are utilized to define the manually cu-
rated profiles for drugs and genes respectively. The relations between a
MeSH Disease and a drug or a gene can be either of therapeutic nature
(the application of the drug or targetting the respective gene or its prod-
ucts has a beneficial effect towards the treatment of the respective disease)
or of a causal/metabolism-pertaining nature.
Binding and
Related
associations
Similarly, the evaluation datasets comprising true and false drug gene pairs
are also derived from CTD. As it has been mentioned in Section 3.2.1,
CTD comprises two types of drug gene associations. Those that represent
a physical binding between a drug and a gene (or its products) and those
that represent the impact of the drug on the gene’s regulatory processes.
For instance, an example of a Related association would be:
Thalidomide results in increased activity of ABCB1 protein.
while,
Diclofenac binds to ALB protein.
is considered as a Binding association.
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Figure 4.6: ROC curves for manually curated profiles
The curves show that CASSANDRA produces comparable prediction perfor-
mance when manually curated profiles are utilized. The algorithm successfully
prioritizes direct (i.e., physically interacting) drug gene associations over the in-
direct ones. Once more, the performance improves when associations containing
Human genes are considered.
Improved
performance
for Binding
associations
As shown in Figure 4.6, the suggested method obtains an AUC value of
0.84 for the Binding subset. When considering only Human genes, the
AUC value rises to 0.86. With respect to the Related drug gene asso-
ciations dataset, CASSANDRA achieves an AUC of 0.77. This value
increases to 0.79 when taking into account only drug-Human gene pairs.
The arithmetic mean of MeSH Diseases related to Human genes in the
CTD subsets Binding and Related is 8 and 4 respectively. In the case of
non-Human genes, the respective means decrease to 6 and 2. This finding
corroborates the fact that the more terms are included in the profile, the
better the predictive efficiency of the algorithm. Another interesting finding
is that the proposed method demonstrates in general a better performance
on the Binding dataset than on the Related dataset. This justifies the
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algorithm’s potential to successfully prioritize the drug-target interactions
over drug gene associations.
The above results clearly demonstrate that the proposed methodology can
utilize either co-occurrence based ontological profiles or manually curated
profiles with a comparable performance. In both cases, the estimation of
the statistical semantic relatedness between these profiles can produce a
meaningful ranking of drug gene associations. Notably, the algorithm pro-
motes in ranking direct drug gene associations (i.e., physically interacting
drug protein associations) over indirect drug gene associations.
Figure 4.7: PR curves for all datasets
All PR curves are plotted for an 1:1 ratio of imbalance between the set of
true and false drug gene associations. As shown, CASSANDRA’s classifica-
tion efficacy on the PR space is consistent to the one demonstrated in the ROC
space. Again, the performance of the algorithm is better on the datasets Drug-
BankApproved and CTDBinding , when these are compared to the performance of
DrugBankExperimental and CTDRelated respectively.
To confirm the algorithm’s efficacy towards drug gene association predic-
tion, the PR curves for the datasets utilized so far are provided. Given a
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specific dataset, Precision is plotted against Recall for different ratios of
imbalance between the set of true drug gene associations and a subset of
randomly selected false drug gene associations.
PR curves are
consistent
Figure 4.7 shows the respective PR curves on an 1:1 ratio of imbal-
ance for the datasets DrugBankApproved , DrugBankExperimental , Yamanishi,
CTDBinding and CTDRelated . As shown, CASSANDRA dominates both
the ROC and the PR space. The results are consistent to the ones sug-
gested by the ROC curves. Given the same recall space, the algorithm
achieves higher precision for the datasets DrugBankApproved and CTDBinding
when these are compared to DrugBankExperimental and CTDRelated respec-
tively. Same is the algorithm’s behavior when different ratios of imbalance
are considered (see Supplementary Material, Figure 7.1). The case of Drug-
BankExperimental dataset is particular. As shown in Figure 4.12 (1st row, 2nd
column), the score distributions for true and false drug gene associations
included in this dataset are very similar. Therefore, when increasing the
ratio of imbalance the performance is expected to drop faster in contrast
with the rest of the datasets.
4.3.1.3 Co-occurrence based vs. manually curated profiles
The suggested methodology can utilize either co-occurrence based profiles
or manually curated profiles and successfully prioritize known drug gene
associations. The arising question is which profile type performs better to-
wards the establishment of latent drug gene associations. Manually curated
profiles are expected to outperform due to their high quality and strongly
established relation to drugs or genes compared to the co-occurrence based
profiles. In this section, the comparison between utilizing manually cu-
rated and co-occurence based profiles towards the discovery of drug gene
associations is described.
To compare the two profile types, all CTD true drug gene associations are
considered. The set of false drug gene associations is compiled as described
in Section 3.2.1. Then, the drug gene associations wherein the drug and
the gene have both manually curated and co-occurrence based profiles are
maintained. These associations basically constitute the intersection of CTD
drug gene associations and the drug gene associations provided by the
Chapter 4. Results 69
suggested methology. Of course, the drug gene pairs wherein the drug and
gene are co-mentioned in literature were excluded. The resulting dataset
i.e., CTDcb&mc, is then used for the comparison between the manually
curated and the co-occurrence based ontological profiles.
Figure 4.8: ROC curves - Manually curated vs. co-occurrence based
profiles
The curves show that CASSANDRA performs better in the case of co-
occurrence based GO profiles than in the case of manually curatedMeSH Disease
profiles. When co-occurrence based profiles of both ontologies are used, the AUC
value equals the one obtained by manually curated profiles. The performance
drops by 6% in the case of co-occurrence based MeSH Disease profiles.
Co-occurrence
GO profiles
outperform in
ROC space
As shown in Figure 4.8, co-occurrence based profiles that constitute of
GO terms outperform manually curated MeSH Disease profiles. The for-
mer achieves an AUC of 0.77 in comparison to the latter that managed
an AUC of 0.76. Surprisingly, when using both GO and MeSH Disease
co-occurrence based profiles, the performance drops to an AUC of 0.75.
Comparing manually curated to co-occurrence based MeSH Disease pro-
files, the former outperformed the latter only by 6%.
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Figure 4.9: PR curves - Manually curated vs. co-occurrence based
profiles
The PR curves are consistent to the respective ROC curves. The co-occurrence
based GO profiles achieve a higher Precision to Recall performance compared
to the manually curated MeSH Disease profiles. Combined co-occurrence based
profiles that consist of both ontologies also manage higher precision than the
manually curated ones within certain ranges of Recall.
Co-occurrence
GO profiles
outperform in
PR space
To insure the aforementioned results, the PR curves are also provided
(see Figure 4.9). The performance of the algorithm is consistent to the
one illustrated by the ROC curves. As shown, the co-occurrence based
GO profiles achieve higher precision for most of the Recall values. Within
the Recall ranges (0.0, 0.2) and (0.85, 1) combined co-occcurrence based
profiles of GO and MeSH Disease terms also managed higher Precision.
When introducing different ratios of imbalance the algorithm’s efficacy is
not substantially affected (see Supplementary Material, Figure 7.2). Co-
occurrence based profiles including GO terms continue to outperform the
rest. When focusing on MeSH Disease terms, the co-occurrence based pro-
files are quite close in performance to the manually curated ones. This
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suggests that co-occurrence information encompasses a sufficient and reli-
able signal of association between two entities.
The impact of GO terms
At this point, the differentiations in the algorithm’s performance pertaining
to the type of ontological terms included in a profile, are further explored.
All datasets for which there exist co-occurrence based ontological profiles
corresponding to drugs and genes are utilized. The evaluation process is
repeated and the algorithm’s efficacy is estimated considering only one type
of ontological terms in each experiment; MeSH Disease or GO terms. The
results are compared to the AUC values obtained when using combined
ontological profiles. Table 4.7 reports the respective findings.
Table 4.7: AUC values for different type of ontological profiles
Combined
profile
Gene
Ontology
MeSH
Disease
DrugBankApproved 0.837 0.842 0.77
DrugBankApproved(HS) 0.875 0.846 0.855
DrugBankExperimental 0.577 0.675 0.393
DrugBankExperimental(HS) 0.772 0.79 0.71
Y amanishi 0.735 0.775 0.655
CTDcb&mc 0.756 0.771 0.71
The datasets comprising drugs and genes with co-occurrence based profiles were
included in the analysis. The AUC is estimated when solely GO or solely MeSH
Disease terms are utilized. The results are compared to the performance achieved
for combined ontological profiles. GO terms boost the performance of the algo-
rithm and have the most intense impact in successfully discriminating true from
false drug gene associations.
GO terms are
the most
beneficial
GO terms were observed to have a significantly larger impact in the pre-
diction performance compared to theMeSH Disease terms. More precisely,
considering only GO terms, the AUC values increase in almost all datasets.
Notable is the case of the DrugBankExperimental dataset wherein GO pro-
files performed better by 14.5% when compared to the combined profiles,
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and by 42% when compared to MeSH Disease profiles. As it has been re-
ported before, Experimental drugs are underrepresented in literature and
the average number of ontological concepts is significantly lower than the
number of concepts included in the profiles of Approved drugs. Evidently,
GO terms are proved to be more efficient in establishing latent associations
between drugs and genes, even when the literature information provided
is limited. These findings are in complete accordance with the results re-
ported in Figures 4.8 and 4.9, wherein the co-occurrence based profiles are
compared to the manually curated ones.
Why are GO
terms more
predictive?
The above analysis suggests that the use of co-occurrence based GO pro-
files can successfully prioritize true from false drug gene associations. But
why do GO terms boost the algorithm’s performance? This is most likely
due to specific nature of GO terms compared to that of MeSH Disease
terms. More specifically, GO constitutes a controlled vocabulary entirely
dedicated to the attributes of genes and their products. These terms may
sufficiently characterise the latent processes that a drug is involved in, in
case the drug and the term share significant mutual information. On the
other hand, diseases are usually a combination of several conditions, func-
tions, processes and symptoms that each one of them can be connected to
several drugs and genes at the same time. Hence, the associations proposed
by the semantic similarity of MeSH Disease terms are not as precise as the
ones derived from the semantic similarity between GO terms.
The type of
terms is
important
To conclude, the results provided in this evaluation part, demonstrate the
potential of co-occurrence based profiles compared to manually curated
profiles towards the prediction of putative drug gene associations. Most
importantly, it is shown, that if co-occurrence based profiles consist of terms
highly precise and descriptive (such as GO terms), they can outperform
manually curated profiles. The contribution of GO terms towards drug
gene association prediction is significantly higher than the contribution of
the MeSH Disease terms. GO terms succeed in efficiently prioritizing true
over false drug gene associations, even when little literature information is
provided. In the end, to establish a relation between two terms, the type
and quality of terms play the same or even more important role than the
way this relation is established in the first place (manually or statistically).
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4.3.2 Performance evaluation - Semantic similarity
In the previous Section (4.3.1), the impact of ontological profiles is ex-
amined based on the way the profiles are generated (manually curated or
co-occurrence based) and the type of ontological terms they comprise (GO
or MeSH Disease terms). In this Section the efficacy of nPMI as a statisti-
cal measure of semantic similarity between the profiles will be investigated.
To demonstrate the results of the metrics comparison the datasets Yaman-
ishi, DrugBankApproved and DrugBankExperimental are utilized. The statisti-
cal semantic similarity nPMI is replaced by the metrics Wu-Palmer and
Lin and the efficacy of the algorithm is estimated respectively (see Section
3.2.2). Both ROC and PR curves are provided (Figures 4.10 and 4.11 re-
spectively). Additionally, we plot density distributions between true and
false drug gene associations produced by the algorithm when each one of
the metrics is considered.
nPMI
outperforms
Wu-Palmer
and Lin
As shown in Figure 4.10, nPMI succeeds the highest AUC value in all
datasets under evaluation. Notably, the metrics Wu-Palmer and Lin when
applied on the Experimental dataset perform worse than the random clas-
sifier. Clearly nPMI constitutes the metric of choice when the provided lit-
erature information is limited and sparse, as in the case of the Experimental
dataset. In all graphs, Lin presents slight improvement when compared to
Wu-Palmer most likely due the fact that as a measure it incorporates the
signal each concept carries in the corpus (i.e., Information Content).
The PR graphs shown in 4.11 are in accordance with the behavior of the
metrics as that displayed in the ROC curves. In all datasets, nPMI statis-
tical semantic similarity interrelates drugs to genes and discriminates true
to false drug gene associations with significantly higher Precision for the
whole range of Recall values.
nPMI has the
highest
discriminative
power
To examine the discriminative power of nPMI versus the metrics Lin and
Wu-Palmer, the Probability Density Functions (PDF s) are designed. For
each one of the datasets, given the number of true drug gene pairs, an equal
number of false drug gene pairs is randomly selected from the respective
subset of false drug gene associations. As shown in Figure 4.12, nPMI
succeeds the highest degree of discrimination between the true and false
drug gene pairs in all datasets.
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Figure 4.10: ROC curves for different metrics of semantic similarity
ROC curves plotting the true positive rate against the false positive rate
of each semantic similarity measure on the datasets DrugBankApproved , Drug-
BankExperimental and Yamanishi. The curves show that nPMI outperforms both
Wu-Palmer and Lin. Lin demonstrates slightly better performance than Wu
Palmer due to the incorporation of the concepts’ Information Content.
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Figure 4.11: PR curves for different metrics of semantic similarity
The PR curves each metric achieves on the datasets DrugBankApproved , Drug-
BankExperimental and Yamanishi are shown. The curves show that nPMI achieves
higher Precision for all Recall values compared to Wu Palmer and Lin metrics.
Again, Lin demonstrates slightly better performance thanWu Palmer due to the
incorporation of the Information Content of the concepts towards the estimation
of semantic similarity.
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Figure 4.12: Density distributions for different measures of semantic
similarity
The Density distributions of the similarity scores assigned to true and false drug
gene pairs produced by each one of the metrics, are provided for the datasets
DrugBankApproved , DrugBankExperimental and Yamanishi. The vertical red and
blue lines represent the arithmetic mean of the scores for the true and false
drug gene pairs respectively. Clearly, nPMI is the most efficient measure to
discriminate true from false drug gene associations in all datasets. Notably, in
the case of the DrugBankExperimental dataset, Wu-Palmer and Lin completely
fail the task; the mean of false drug gene pairs is greater than the mean of the
scores assigned to true drug gene pairs.
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More specifically, the arithmetic mean of the scores assigned to true drug
gene pairs by nPMI is always greater than the mean assigned to the false
drug gene pairs scores. Moreover, when calculating the difference of the
true to false mean values again nPMI outperforms. Interestingly, when ap-
plied on the DrugBankExperimental dataset, the metrics Lin and Wu-Palmer
completely fail to discriminate true from false drug gene pairs. As shown
in Figure, the mean values for the density distributions of the false drug
gene pairs are greater than the mean values for the density distributions of
the false drug gene associations (for analytical mean values, see Table 7.1
in Supplementary Material).
KS test and
t-test are
concordant
To further assess the discriminative power of each metric of semantic
relatedness, the statistical Student’s t-test is performed. The respective
statistical test computes the probability of the null hypothesis, meaning
the probability that two sets of scores come from the same distribution.
A probability less than 0.05 signifies that the respective metric can dis-
criminate with statistical significance the two distributions. Additionally,
the Kolmogorov-Smirnoff (KS ) statistical test is applied. For both true
and false drug gene association scores, the distance between the respec-
tive Empirical Cumulative Distribution Function (ECDF ) distributions is
computed, according to the KS test. Briefly, the greater the distance be-
tween two ECDF distributions, the higher the discrimination degree be-
tween them. Tables 4.8 and 4.9 collectively report the probability, ECDF
distances and AUC scores for every dataset constituted by drugs and genes
with co-occurrence based or manually curated profiles respectively.
nPMI
outperforms
According to the values reported in Tables 4.8 and 4.9, the statistical sim-
ilarity measure nPMI systematically achieves the highest AUC values in
all datasets, whether co-occurrence based profiles (see Table 4.8) or man-
ually curated profiles (see Table 4.9) are used. Moreover, nPMI manages
to efficiently discriminate true from false drug gene pairs with statistical
significance. Even in the case of the datasets DrugBankExperimental and Ya-
manishi, nPMI achieves the lowest p-value. Additionally, when nPMI is
utilized, the distance between the ECDF distributions of the scores for true
and false drug gene pairs is the highest.
What is the explanation behind nPMI ’s efficacy towards the estimation of
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semantic similarity between drugs and genes? Two are the basic charac-
teristics that differentiate nPMI from the Wu-Palmer and Lin metrics.
nPMI doesn’t
depend on the
structure of
the ontology
First, nPMI is a statistical and fully corpus-based metric which ignores
the structure of the ontology, meaning the relationships between the terms.
When applying nPMI, the concepts that constitute the respective ontology,
are simply treated as a set of terms, i.e., a lexicon, wherein the similarity
between them is estimated solely based on the degree of their co-occurrence
in MEDLINE indexed titles and abstracts. This accounts for the general
applicability of the method across different ontologies and has a positive
impact on the method’s performance. More precisely, the statistical mea-
sure nPMI spots similarities between concepts which are not detected by
any other measure that is based on the hierarchy of the ontology. With
the use of nPMI these pairs of concepts participate in the calculation of
the association score between a drug and a gene. Consequently, this has
a beneficial effect on the recall of the method, since additional drug gene
associations can be suggested.
nPMI
uncovers
hidden
similarities
In particular, nPMI is able to assign a similarity score between GO terms
which belong to different subontologies, e.g., a term from the Biological
Process and a term of the Molecular Function subontology if there is sub-
stancial co-occurrence data. Accordingly, similarity can be computed be-
tween a MeSH Disease and a GO concept. In the cases described above,
the measures Wu-Palmer and Lin would assign a zero similarity score.
Wu-Palmer and Lin would also fail to compute any semantic relatedness
between two MeSH Disease terms wherein the latter is a symptom of the
former. More precisely, let us consider Prader-Willi Syndrome, a congenital
disease affecting many parts of the body. According to the MeSH defini-
tion, the symptoms of this disease include Hypogonadism. A quick look up
in the MeSH hierarchy shows that the Lowest Common Ancestor (LCA)
of Prader-Willi Syndrome and Hypogonadism is the root. Consequently,
both Wu-Palmer and Lin would assign a 0.0 similarity to these concepts,
while nPMI assigns a score of 0.42.
nPMI
prioritizes
hidden
associations
The second characteristic of nPMI is the ability to discriminate concept
pairs based on their frequency. Pairs composed of low-frequency terms
receive a higher score compared to the ones composed of high-frequency
terms (Manning and Schu¨tze, 1999). More precisely, let us consider two
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concept pairs that constitute of concepts that are semantically close, mean-
ing concepts that are close in the ontology tree. If one pair is frequent (and
hence general) and the other pair is rarely found in text, then the latter
is more informative than the former. With the use of nPMI this differ-
ence is captured and represented in the association score between a drug
and a gene. Highly frequent concept pairs contribute less to a drug gene
association score than pairs of lower frequency. This explains why nPMI
performs better than the traditional measures of semantic similarity. Table
4.10 shows an example of this phenomenon.
Table 4.10: nPMI computations - Examples
Pair A Pair B
Coronary
Disease
Myocardial
Ischemia
Kearns-Sayre
Syndrome
Ophthalmo-
paresis
nCd/g 164, 596 55, 757 514 846
nCd,Cg 18, 136 134
distance 1 2
nPMI 0.46 0.71
Wu-Palmer 0.89 0.83
The table reports the difference between the similarity scores assigned by nPMI
and Wu-Palmer on two different concepts pairs. The distance between the con-
cepts which constitute the pairs is reported along with the occurrence and co-
occcurrence values of the terms. nPMI prioritizes the less frequent and hence,
more informative concept pairs.
Assume Cd = Coronary Disease and Cg = Myocardial Ischemia two terms
that participate in the profile of a drug d and a gene g respectively. Ta-
ble 4.10 reports the number of MEDLINE documents where Cd occurs
(nCd), the number of MEDLINE documents where Cg occurs (nCg), and
the number of MEDLINE documents where Cd and Cg co-occur (nCd,Cg).
It additionally reports the distance of the terms in the ontology tree and
two values of semantic similarity. The nPMI and the Wu-Palmer seman-
tic similarity. Next, assume the pair Cd = Kearns-Sayre Syndrome and
Cg = Opthalmoparesis, for which the respective numbers are also reported.
This example shows that for two pairs of concepts that are semantically
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close, though the number of occurrences and co-occurrences of the first
pair is significantly higher than the respective values of the second pair,
the second pair receives much higher nPMI score. Through this exam-
ple we can observe that the application of nPMI enables the identification
of latent relations between ontological terms that do not necessarily oc-
cur very frequently, as in the case between Kearns-Sayre Syndrome and
Opthalmoparesis where the former is a syndromic variant of the latter.
nPMI prioritizes these pairs in comparison to other frequent and hence
less informative concept pairs.
Conclusively, nPMI is an efficient measure of semantic relatedness between
two ontological concepts. Comparison against the traditional metrics Wu-
Palmer and Lin demonstrates that nPMI has the best performance and
the highest discriminative power. The suggested measure of semantic sim-
ilarity spots associations between two concepts that the other metrics fail
to reveal. Even when suggesting the same concept pairs, nPMI prioritizes
the more informative relations.
4.4 Drug repositioning
Literature
before
repositioning
We manually mine the literature and compile a set of drugs repositioning
cases (see Section 3.2.1.2). Table 4.11 shows the analysis of the application
of the suggested method in identifying new indications for existing drugs.
We focus on the last 5 years and collect the drug repositioning cases that
were approved by FDA and that correspond to drugs for which we have
profiles. The drug profiles are generated based on literature data before
the year of approval of each repositioning case. The table illustrates the
old and new indications for each of the examined drugs along with their
positions in the list of the drugs’ profile terms.
New
indications
rank high in
profiles
As the table suggests, in almost all cases the old indications appear in the
top 3 associated disease terms of the drug. In parallel, the new indications
are always included in the co-occurrence based profiles of drugs among the
top 30 associated disease terms of the respective profiles. To assess the
association between a drug and the respective new incication, 2 types of
z -scores are computed. The first is the z -score the new indication achieves
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inside the profile of the drug. The second z -score corresponds to the overall
distribution of drug-MeSH Disease associations. As shown, themean of the
z -score of an old indication both in the profile of the drug and in the overall
distribution (3.94 and 4.19 respectively) is higher than that of the new
indication (2.02 and 2.41 respectively). This is expectable if we consider
that the old indications of the drugs are more discussed in literature than
the new indications. The results of this analysis suggest CASSANDRA
can be utilized towards the identification of new indications for already
existing drugs.
4.5 Case studies
In the following CASSANDRA’s potential towards drug gene association
prediction and drug repositioning is illustrated via three case studies. In
all three cases, the findings in the scientific literature that support the
proposed associations are provided along with the respective graphical rep-
resentations.
4.5.1 Cathine-GHRL association
In Figure 4.13, all the hypotheses suggesting an association between Cathine
(DrugBank : DB01486) andGHRL (EntrezGene: 51738) are shown. Cathine,
which is a psychotropic compound, is selected because it is among the Drug-
Bank compounds which do not have any target information. Altogether,
11, 302 human genes were ranked against Cathine. GHRL, a gene coding for
the growth hormone-releasing peptide ghrelin, ranks among the top 0.4%
of these genes (position 54) with a z -score of 2.83 and a p-value< 0.05.
Hyperphagia-
Bulimia
Table 4.12 shows representative textual pieces of evidence suggesting this
association which is discovered by CASSANDRA. Cathine and GHRL
are interconnected via the concepts Hyperphagia (MeSH : D006963) and
Bulimia (MeSH : D002032). According to MeSH, Bulimia is a form of Hy-
perphagia. The association emerges as follows: Cathine is isolated from the
plants Catha Edulis and Ephedra Sinica, and acts as a stimulant. It is a
Phenylpropanolamine (PPA) isomer, along with Norephedrine. There exist
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Figure 4.13: Cathine - GHRL
The figure illustrates the intermediate connections of Cathine to GHRL. Clearly,
the most surprising connection is established via the concepts Single Fertilization
and Spermatogenesis that pertain to Reproduction. These concepts are seman-
tically quite distinct from the Eating Disorders concepts to which Cathine and
GHRL have known relations.
several studies reporting the appetite imminent suppressive role of PPA’s
(PMID: 3703896; 7855211). Studies regarding the effects of PPA on dif-
ferent types of Hyperphagias conclude that PPA sufficiently suppresses ap-
petite in hyperphagic rats (PMID: 3310024). All the above support the hy-
pothesis that Cathine suppresses Hyperphagia as an phenylpropanolamine
isomer. As a result, Cathine may also be effective in restraining Bulimia.
In parallel, ghrelin is the only known hunger-stimulating hormone and
is related to several eating disorders including Bulimia Nervosa (MeSH :
D052018) (PMID: 21453750). It is reported that when increasing the levels
of ghrelin via its direct injection into the brain ventricles, the consumption
of rewarding foods in mice and rats increases, as well (PMID: 21354264).
In the same paper it is stated that ghrelin receptor (GHS-R1A) antagonists
show beneficial effects towards the suppression of food intake. In addition,
it is also stated that variations in the GHS-R1A and pro-ghrelin genes have
een associated with Bulimia Nervosa and obesity.
Anorexia
Cathine can also be connected to GHRL via Anorexia (MeSH : D000855).
Cathine’s product information describes the drug as anorexic. It has also
been stated that ghrelin in hypothalamic neurons controls Anorexia and
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Cachexia (MeSH : D002100) (PMID: 22632865). The theurapeutic applica-
tions of ghrelin towards these conditions have been also discussed (PMID:
21635929).
GPCR activity
Moreover, Cathine is involved inG-protein Coupled Receptor Activity (GO :
0004930) (PMID: 17158213), and ghrelin’s receptor is also a G-protein
coupled receptor (PMID: 16382107).
Phosphorylase
Activity
In addition, an increase in the adrenal Phosphorylase Activity (GO : 0004645)
has been observed after the administration of Cathine (PMID: 7903110). In
the same study, it is also reported that the glycogen levels were decreased.
Other studies in tundra vole (Microtus oeconomus) (PMID: 15302267) show
that after the injection of intraperitoneal ghrelin, kidney Glycogen Phos-
phorylase Activity (GO : 0008184) increased, whilst kidney glycogen levels
decreased. The above suggests similar responses after ghrelin’s or Cathine’s
administration.
Unexpected
relation to
Reproduction
The last connection is a surprising one, since it is formed via the concepts
of Single Fertilization (GO : 0007338) and Spermatogenesis (GO : 0007283).
Both concepts pertain to reproduction. Studies in incapacitated mouse
spermatozoa, markedly demonstrate that cathine significantly accelerates
capacitation (PMID: 15513978; 17158213). Additionally, observations in
normal adult rats suggest ghrelin’s modulative role in Spermatogenesis
(PMID: 22360851;22658447).
Conclusively, all the described links above account for the hypothesis that
Cathine and GHRL are associated. Although, both the drug and the gene
are known to be related to Eating Disorders, their association is intensified
by the discovery of a new intermediate connection that exists between them;
the connection pertaining to Reproduction.
4.5.2 Fenethylline-ApoE association
The second example suggests a connection between the gene ApoE and the
drug Fenethylline (Figure 4.14 and Table 4.13 give the respective overview).
ApoE ranks among the top 5 in the ranked list of 11, 302 Human genes with
a z -score of 4.27 and a p-value< 0.05.
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Table 4.12: Cathine-GHRL textual findings
Relation Textual Evidence
Cathine is also called PPA Cathine, ... is one of the optical isomers of
phenylpropanolamine (PPA), Wikipedia
PPA suppresses hyperphagia PPA is capable of suppressing appetite in
rats made hyperphagic by various stimuli
(PMID:3310024)
Bulimia is an Hyperphagia MeSH
Ghrelin is involved in bulimia Ghrelin increases food intake ... rele-
vance in the regulation of bulimia nervosa
(PMID:21453750)
Cathine is an anorexic drug Product Information
Ghrelin controls cachexia Ghrelin in concert with hypothalamic
neurons control anorexia and cachexia
(PMID:22632865)
Cathine affects phosphorylase
activity
After the administration of cathine, an increase
in the adrenal phosphorylase activity has
been observed (PMID:7903110)
Glycogen phosphorylase activ-
ity is a phosphorylase activity
Gene Ontology
Ghrelin affects Glycogen phos-
phorylase activity
After the injection of intraperitoneal ghrelin ,
kidney glycogen phosphorylase activities
increased (PMID:15302267)
Cathine affects adrenergic re-
ceptors
Regulation of adenylyl cyclase/cAMP in a
G protein-mediated fashion by cathine
may possibly involve adrenergic receptors
(PMID:15513978)
Adrenergic receptors are G-
protein coupled receptors
Gene Ontology
Ghrelin ’s receptor is aG-protein
coupled receptor
Growth hormone secretagogue receptor is a G-
protein coupled receptor that binds ghrelin
(PMID:16382107)
Cathine boosts single fertiliza-
tion
Cathine can enhance chances of fertilization
in vivo (PMID:17158213)
Single fertilization and sper-
matogenesis pertain to reproduc-
tion
Gene Ontology
Ghrelin modulates spermatoge-
nesis
Ghrelin may be considered as a modulator of
spermatogenesis (PMID:22360851)
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Figure 4.14: Fenethylline-ApoE
The figure shows the intermediate connections of Fenethylline to ApoE. Both the
drug and the gene are strongly related to cardiovascular conditions, which are
expressed either as conditions directly related to heart diseases or as conditions
affecting the retinal area.
Fenethylline is a stimulant compound and has been used for the treatment
of Hyperkinesia and depression (PMID: 23420919). When metabolised is
forming the substances Amphetamine and Theophylline (PMID: 5496920).
Apolipoprotein E is a mediator of liver endocytosis and it has been char-
acterised as a major genetic risk factor for Alzheimer’s disease (PMID:
22622580).
Retinal Vein
Occlusion -
Macular
Edema
The first hypothesis is formed via the interrelated concepts Retinal Vein
Occlusion (MeSH: D012170) and Macular Edema (MeSH: D008269). Ac-
cording to the respective MeSH definition Retinal Vein Occlusion is the
condition describing the blockage of the retina. It is a high risk condition
for patients with Diabetes or several cardiovascular diseases. Three cases
of hemorrhagic central Retinal Vein Occlusion following continuous uses
of Fenethylline have been reported (PMID: 20214057). In the same study
is also stated that after the discontinuation of the drug, the symptoms
markedly withdrew. Following the MeSH definitions, Macular Edema is
the accumulation of fluid or protein around the macula of the eye and it is
oftenly seen with retinal occlusive diseases (PMID: 23410812; 22823029).
Besides, another study characterises the APOE gene polymorphism as a
risk factor for the severity of Macular Edema (PMID: 11910554).
Thrombosis-
Hyperhomo-
cysteinemia
Secondly, two more concepts relate Fenethylline to ApoE. As it has been
already mentioned, Fenethylline forms Amphetamine which is associated
with Arterial Thrombosis (MeSH : D013927) (PMID: 20118172). Results
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prove that Hyperhomocysteinemia (MeSH : D020138) is the most common
condition that is highly associated with both Venous and Arterial Throm-
bosis (PMID: 22933895). Generally, there has been a long-recognized con-
nection between high levels of Homocysteine (Hyperhomocysteinemia) and
Thrombosis (PMID: 22461473). Concomitantly, another study suggests
that ApoE4 (one of ApoE ’s isoforms) is related to Hyperhomocysteine-
mia (PMID: 17158432). Moreover, in scientific literature null-ApoE mice
are extensively used in the study of Hyperhomocysteinemia effects (PMID:
22704348; 23017835; 20696152).
Adding it together, the above information suggests a putative association
between Fenethylline and the processes wherein the gene ApoE is involved.
4.5.3 Milnacipran-SLC6A4 association
The following case study represents the repositioning potential of CAS-
SANDRA. It describes the known association between the drugMilnacipran
(DrugBank : DB04896) and the gene SLC6A4 (Entrez Gene: 6532), which
codes forMilnacipran’s known target, serotonin transporter (SERT ). SERT
ranks at the top (1st) of the list of 11, 302 Human genes with a z -score of
4.48 and a p-value< 0.05.
Milnacipran is a serotonin-norepinephrine reuptake inhibitor (SNRI ) ini-
tially approved for the treatment of Depression (MeSH : D003863) (1996).
In January 2009 Milnacipran was also approved for the treatment of Fi-
bromyalgia (MeSH : D005356). The SLC6A4 gene codes for the serotonin
transporter, which is the target protein of many antidepressant medica-
tions and whose polymorphic region is associated with a variety of anxiety-
related traits and susceptibility for Depression (PMID: 17726476).
Figure 4.15 shows the suggested connections and Table 4.14 summarizes
the textual pieces of evidence that support them. The connections are
generated from MEDLINE abstracts and articles published before 2009,
when Milnacipran was repositioned to Fibromyalgia.
Serotonin
Uptake
Regulation
The first connection is formed via the interrelated concepts of Inhibition
of Serotonin Uptake (GO : 0051614) and Regulation of Serotonin Uptake
(GO :0051611). Milnacipran belongs to the class of SNRIs. SNRIs increase
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Figure 4.15: Milnacipran-SLC6A4
The figure demonstrates the indirect connections for the known association Mil-
nacipran to its target-coding gene SLC6A4. The connections are generated from
data published before 2009. As shown, Fibromyalgia, a condition to which Mil-
nacipran was repositioned after 2009, participates in the establishment of the
respective association.
the levels of serotonin, by blocking SERT which is responsible for the
Regulation of Serotonin Uptake.
Fibromyalgia
The second concept relatingMilnacipran to SERT is Fibromyalgia (MeSH :
D005356). Several articles describe clinical trials and report the efficacy of
Milnacipran in the treatment of Fibromyalgia more than 4 years before
the compound has been approved for use against that condition (PMID:
15378666; 16206355). Other reports confirm that the polymorphic region
of SLC6A4 is associated to Fibromyalgia (PMID:11920428;10555044).
Bulimia &
IBS
Moreover, Milnacipran may have a beneficial effect in the treatment of Bu-
limia nervosa (PMID: 12650949; 18728825). Several articles also state the
association of SERT polymorphisms to eating disorders and in particular
to Bulimia nervosa (PMID: 20209488; 14987118; 12768277). The last con-
nection is formed via the concept Irritable Bowel Syndrome (IBS, MeSH :
D043183 ) which is a condition co-morbid with Fibromyalgia. Experiments
conducted in rodents show that Milnacipran has a potential in the treat-
ment of IBS (PMID: 21996314). Other studies suggest that SLC6A4 is
a candidate gene potentially involved in the pathogenesis of IBS (PMID:
22457857; 23594334).
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The above pieces of evidence confirm that the proposed methodology in-
cludes in the prediction of drug gene associations medical conditions that
can be considered as repositioning candidates.
Table 4.13: Fenethylline-ApoE textual findings
Relation Textual Evidence
Fenethylline causes retinal vein
occlusion
...3 cases of hemorrhagic central textbfretina
textbfvein textbfocclusion following continuous
use of textbffenethylline (PMID:20214057)
Macular edema is associated
with retinal vein occlusion
...treatment of macular edema associated
with central retinal vein occlusion...
(PMID:22823029)
Macular edema is affected by
ApoE
...allele of apolipoprotein E gene is a potential
risk factor for the severity of macular edema...
(PMID:11910554)
Fenethylline forms am-
phetamine
Fenethylline, when metabolised is forming the
substances theophylline and amphetamine,
(PMID:5496920)
Amphetamines increase arte-
rial thrombosis incidence
Amphetamines induce tissue factor ... arterial
thrombosis is in turn triggered by tissue factor
(PMID:20118172)
Arterial thrombosis is resonsi-
ble for hyperhomocysteinemia
Hyperhomocysteinemia proves to be the
most common condition highly associated
with both venous and arterial thrombosis
(PMID:22933895)
Hyperhomocysteinemia is re-
lated to ApoE
Apolipoprotein E e4 allele affects risk of hy-
perhomocysteinemia (PMID:17158432)
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Table 4.14: Milnacipran-SLC6A4 textual findings
Relation Textual Evidence
Milnacipran is a serotonin-
norepinephrine reuptake in-
hibitor
Wikipedia
Inhibition of serotonin uptake
is a regulation of serotonin up-
take
Gene Ontology
SERT is responsible for the reg-
ulation of serotonin uptake
Wikipedia
Milnacipran cures fibromyalgia In this Phase II study, milnacipran led
to statistically significant improvements in
pain and other symptoms of fibromyalgia
(PMID:16206355)
SLC6A4 polymorphism is related
to fibromyalgia
Confirmation of an association between fi-
bromyalgia and serotonin transporter pro-
moter region polymorphism (PMID:11920428)
Milnacipran treats bulimia ner-
vosa
Milnacipran in the treatment of bulimia ner-
vosa: a report of 16 cases. (PMID:12650949)
SLC6A4 polymorphism is related
to bulimia nervosa
The serotonin transporter, encoded by the
SLC6A4 gene, may also have an important
role in eating disorders, as its availability is
decreased in patients with bulimia nervosa...
(PMID:14987118)
Milnacipran treats Irritable
Bowel Syndrome
...milnacipran has potential clinical applica-
tion in the treatment of visceral pain, such as in
irritable bowel syndrome... (PMID:21996314)
SLC6A4 is a biomarker of Irri-
table Bowel Syndrome
...suggesting that SLC6A4 is a potential can-
didate gene involved in the pathogenesis of Ir-
ritable Bowel Syndrome. (PMID:22457857)
Chapter 5
Discussion
This Chapter discusses the outcome of the current study. The implemen-
tation decisions taken for the realization of the task at hand are explained.
CASSANDRA is compared against other methodologies of Literature
Based Discovery and drug gene association prediction. More specifically,
the following are discussed
• How does CASSANDRA differentiate from the rest of the method-
ologies implemented towards drug gene association prediction?
• Why focusing on Literature Based Discovery? How is CASSAN-
DRA contributing to the field?
– Why utilizing titles and abstracts is sufficient?
– What are the advantages of co-occurrence?
• The role of ontologies; why GO and MeSH Disease terms?
– What is the impact of the statistical semantic similarity mea-
sure? Which measure is the most appropriate?
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Overview of
CASSANDRA
In this work we introduce CASSANDRA; an algorithm for the automated
extraction of candidate drug gene associations from biomedical text on the
large scale. CASSANDRA combines standardized text mining techniques
and biomedical ontologies. It constitutes an unsupervised approach that
predicts new drug gene associations solely by systematically analysing the
co-occurrence of biomedical terms in the scientific publications indexed by
MEDLINE.
More specifically, drug and gene names are obtained from the popular and
well-established repositories DrugBank and UniProtKB respectively. The
ontological terms belong to the widely used terminologies Gene Ontology
(GO) and Medical Subject Headings (MeSH ). The proposed algorithm uti-
lizes the Pointwise Mutual Information (PMI ) to rank the most related
GO and MeSH Disease concepts to the drug and the gene respectively.
These concepts form an individual profile for each drug and gene. Then,
by quantifying the statistical semantic relatedness between these profiles,
CASSANDRA assesses and prioritizes the associations between drugs and
genes. The degree of semantic similarity between a drug and a gene profile
signifies the strength of their association.
Results
overview
CASSANDRA successfully identifies direct drug gene associations with
high precision and prioritizes them over indirect associations (i.e., associ-
ations wherein the drug affects a certain gene product without necessarily
binding physically to it). Validation shows that the algorithm achieves
an Area Under the Curve (AUC ) up to 0.88 for a dataset consisting of
Approved drugs and Human genes. Additionally, the statistical analysis
demonstrates that the proposed semantic similarity metric is more efficient
compared to traditional measures towards the discrimination of true from
false drug gene associations.
Co-occurrence
based profiles
are efficient
The use of co-occurrence based profiles doesn’t at all affect the perfor-
mance of the algorithm. On the contrary, the results show that profiles
of ontological terms generated from co-occurrence based statistics have
a comparable and, at times better, performance than the manually cu-
rated profiles. Evidently, the generated profiles can provide an insight into
biomedical properties for drugs and genes and contribute to the inference of
associations that might not have been included in a database nor explicitly
reported in the literature.
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Disease-based
drug
repurposing
Notably, CASSANDRA can support drug repurposing not only in a tar-
get based fashion (meaning to propose new genes related to drugs), but also
in a disease-based fashion. Indicatively, for all FDA approved drugs repo-
sitioned over the last 5 years, co-occurrence based profiles were generated
from publications before 2009. The analysis shows that the new therapeu-
tic indications are always included in the profiles and rank relatively higher
than the rest of the conditions.
5.1 Drug gene association prediction
Significant
differences
from
traditional
methods
In Table 2.3 we provide an overview of methodologies implemented for
drug gene association prediction. Evidently, CASSANDRA significantly
deviates from traditional drug gene association prediction. The proposed
algorithm is among the very few unsupervised methodologies utilized for
this task. As shown, it is also among the very few approaches that apply
drug gene association prediction on the large scale. Instead of learning from
structural and sequence similarity of drugs and genes respectively, CAS-
SANDRA utilizes ontologies and literature data. One major advantage is
that, unlike other methods, CASSANDRA doesn’t require existing drug
target information to predict a new associated gene for a drug.
Training
independence
Due to the unsupervised nature of CASSANDRA, the method needs no
training data. This is particularly advantageous in the case of drug gene
association prediction, wherein the lack of benchmark datasets poses a sig-
nificant problem. In fact, there is only one benchmark dataset introduced
by Yamanishi et al. on 2008. Since then, the respective dataset has been
the predominant means to cross-compare the mainly supervised methods
implemented towards drug-target interaction prediction. The works van
Laarhoven and Marchiori (2013), Fakhraei et al. (2013) and Go¨nen (2012)
are just a few examples.
Dataset
independence
However, the limitation of such dataset is that it contains only true-positive
drug target interactions. The negative interactions are generated by the
pairwise combination of all drugs and targets contained in the true-positive
dataset, as it has been also the case for the evaluation datasets generated
within this study. That is the Achilles’ heel in machine learning approaches.
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In the end, the models learn only from positive data, since there is no way
to obtain and hence train a classification model over true-negative drug
target interactions (Pahikkala et al., 2014; Ding et al., 2013). As a matter
of fact, it is such the dependence of some methods on the training dataset
that they are unable to predict a drug target interaction between a drug
and target that do not have already known interaction information with
other targets and drugs respectively. Alaimo et al. (2013), Cheng et al.
(2012a), Laarhoven et al. (2011) and Yamanishi et al. (2010) constitute
representative examples of such methodologies. CASSANDRA, on the
other hand, remains independent of the dataset features; apart from its
unsupervised implementation, the proposed algorithm focuses on the pri-
oritization of drug gene associations rather than their binary classification
to true and false drug-target interactions. All drug gene pairs are assigned a
score which represents the strength of the association, regardless of whether
the drug or the gene already participate in known drug target interactions.
Scalability
An additional advantage stems from CASSANDRA’s unsupervised im-
plementation. The algorithm is able to process massive literature data and
predict drug gene associations on the large scale. On the other hand, su-
pervised large scale classification is an increasingly Big Data problem and
so far little has been published towards the practical resolution of this is-
sue (Sun et al., 2014). It has been shown that the performance of Support
Vector Machine classification on large-scale taxonomies is ”far from satis-
factory” (Liu et al., 2005). In methods applying the Bipartite Local Model
(BLM ) (e.g., Alaimo et al. 2013, Yu et al. 2012, Perlman et al. 2011) or
the Pairwise Kernel Method (PKM ) (e.g., Takarabe et al. 2012, Jacob and
Vert 2008) this issue is intensified (Ding et al., 2013). That explains why
the majority of the supervised methods addressing drug target prediction
focus on the readily available yet size-restricted dataset of Yamanishi et al.
(2008).
Current
supervised
methods are
overoptimistic
The outbreak of machine learning approaches towards drug target predic-
tion received the notice of Pahikkala et al. (2014), who in a recent study
examine the quality of the respective methodologies. Pahikkala et al. claim
that the striking performance of these methods is unrealistic. They suggest
that the problem of drug target interaction prediction should be formu-
lated as a prioritization problem rather than a binary classification prob-
lem. They also state that the currently used evaluation datasets are not
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appropriate for the task at hand and they propose the use of biochemical se-
lectivity assays. Moreover, they experimentally demonstrate 2 more factors
that dramatically affect the prediction results of several supervised learning
studies (e.g., Mei et al. 2013, Laarhoven et al. 2011). The former pertains
to the evaluation procedure; they show that simple cross-validation leads
to overoptimistic performance. Lastly, they pinpoint the bias between the
training and test sets, meaning the common shared drugs, targets or drug
target interactions.
Even so, such an overoptimistic viewpoint towards the evaluation procedure
can be found in unsupervised methodologies, as well. Although elementary
and on an early stage, the approach of Plake (2010) constitutes a repre-
sentative example. The idea shares common ground with CASSANDRA
but fails to produce meaningful drug gene associations mainly because it
applies no filtering on the concepts that form the associations between
drugs and genes. Most importantly, in this work, drug gene association
prediction is evaluated only on an in-house built dataset which includes
a 70% percent of zero-scored drug gene associations. Consequently, the
proposed method shows an exceptional performance. However, when ap-
plied on other datasets the method’s efficacy drops dramatically. Already,
in Section 4.3.1.1 we show how influencing is the inclusion of zero-scored
associations when assessing the algorithm’s efficacy. The quality of the
evaluation dataset is indeed an issue that requires particular consideration.
Taking all the above into account, it is evident that CASSANDRA con-
stitutes a robust method towards drug gene association prediction. This is
also corroborated in Section 4.3.1.1, wherein the efficacy of the algorithm
is assessed by its application on a series of differentiated datasets. The
formulation of the problem as a prioritization task proves to be more re-
alistic towards drug gene association prediction. CASSANDRA doesn’t
depend on training and test data, hence it remains bias free. Lastly, follow-
ing an unsupervised methodology enables to perform drug gene association
prediction on the large scale.
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5.2 Exploring the literature
Hidden
information
Biomedical literature constitutes a valuable source of information. How-
ever, it remains unexplored mainly due to its vast volume. With more
than 400, 000 articles published every year, the task to stay current with
the literature could easily occupy 75% of a scientist’s working day (Cheng
et al., 2008). Investigating hidden associations in the plethora of relation-
ships reported in scientific articles could be considered easily as searching
a needle in the haystack. Still, it is highly significant to leverage from that
information that is usually not yet included in biomedical repositories. The
latter is exactly acknowledged by the very concept of Literature Based Dis-
covery and by the variety of tools developed towards the automation of
this procedure (see Table 2.1).
CASSANDRA focuses on Literature Based Discovery, the (semi)-automatic
inference of implicit knowledge out of literature (Weeber et al., 2005). The
serendipitous discovery of Swanson that related Fish Oil to Raynaud’s
Syndrome (Swanson, 1986) remains the core motivation basis of CAS-
SANDRA. The algorithm projects this approach to drug gene association
prediction and attempts the systematic and automated retrieval of relevant
hypotheses from the biomedical literature.
Expanding the
ABC model
Unlike existing tools in the domain of Literature Based Discovery (see
Table 2.1), CASSANDRA takes a step further and deviates from the con-
ventional ABC model by incorporating the notion of two intermediate, yet
similar concepts B. As stated in Cameron et al. (2013), relevant information
may exist in longer chains of concepts semantically connected. CASSAN-
DRA generates such longer chained hypotheses and ranks them towards
the identification of indirectly connected drugs and genes that would be
difficult to uncover without computational assistance or prior knowledge.
Harnessing
ontologies
Additionally, CASSANDRA is one of the Literature Based Discovery
methods that fully utilize ontologies. As shown in Table 2.1, ontologies,
although constituting useful and controlled vocabularies, are not exten-
sively used towards the establishment of hypotheses. Most of the tools im-
plemented use their in-house defined terminologies and this hinders their
general applicability. CASSANDRA uses ontologies to explore the liter-
ature and more precisely, it systematically applies the whole range of GO
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and MeSH Disease terms towards the establishment of hypotheses pertain-
ing to drug and gene relations. An additional feature that differentiates
CASSANDRA from the majority of Literature Based Discovery tools is
the statistical refinement of the associations that establish the drug gene
predictions. Besides using a probabilistic tool (i.e., nPMI ) to establish
these associations, CASSANDRA applies a further filtering to insure the
quality of the generated hypotheses.
Few
literature-based
approaches
Moreover, CASSANDRA constitutes one of the few methods that solely
utilize the biomedical literature to generate drug gene association predic-
tions (see Table 2.3). Zhu et al. (2005) learn from gene-gene, compound-
compound and gene-compound co-occurrence data in a preselected set
of MEDLINE abstracts and suggest implicit compound-gene associations.
Wu et al. (2012) collect drug gene co-occurrence data on a subset of MED-
LINE abstracts and utilize Latent Dirichlet Allocation to prioritise them.
However, both methodologies do not attempt a large scale drug gene as-
sociation prediction. Indeed, only a small subset of MEDLINE records is
used in each case (∼ 0.4% and 1.0% respectively). In the study of Zhu
et al. (2005) this is somewhat explainable, since supervised approaches are
generally difficult to scale (Wang et al., 2008). Additionally, Wu et al.
(2012) focus on the prioritization of directly co-occurring drugs and genes,
while CASSANDRA excludes such pairs and focuses on the prediction of
indirectly related drugs and genes.
Prediction for
all drugs and
genes
Utilizing the biomedical literature lends CASSANDRA an additional im-
portant feature. Unlike several mainly supervised strategies towards drug
target interaction prediction, CASSANDRA is able to provide ranked lists
of associated genes for drugs with no known targets and ranked lists of as-
sociated drugs for non-coding (or at least reported as such) target genes.
Of course, the only prerequisite is that the existing literature enables the
generation of statistical significant co-occurrence based profiles for these
drugs and genes.
5.2.1 Focusing on abstracts and titles
When it comes to text mining applications the arising question is: ”Which
text to mine?” CASSANDRA utilizes co-occurrence data fromMEDLINE
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indexed abstracts and titles. Notably, there are many tools utilizing the
same resource towards the extraction of biomedical information (Gijo´n-
Correas et al., 2014; Kim et al., 2013b; Fontaine et al., 2011; Frijters et al.,
2010). The main reason for that is their public accessibility (Vincze et al.,
2008). Only ∼ 2% of MEDLINE entries have open-access full-text articles
available for text mining (Thomas et al., 2012).
Abstracts
deliver
information
Another reason is that the experimental procedures or results described
in full-text articles are hard for researchers to re-use (Ne´ve´ol et al., 2011).
In a recent study, Fontelo et al. (2013) also state that abstracts appear to
be equally informative as full-text articles. Most importantly, it has been
demonstrated that text mining tools perform better in abstracts than on
article bodies (Cohen et al., 2010b). This can be possibly attributed to the
fact that, unlike full-text articles, abstracts contain less hedgy sentences
(Fontelo et al., 2013), and state clearly the respective research findings
(Jenssen et al., 2001). All the arguments stated above opt for the use
of abstracts over full-text articles. Still, this doesn’t necessarily rule out
the additional use of full-text articles by the suggested methodology in the
future.
5.2.2 Using co-occurrence
Co-occurrence is often applied in biomedical relation extraction and par-
ticularly in Literature Based Discovery (Paik et al., 2014; Cheung et al.,
2013; Tsuruoka et al., 2011; Frijters et al., 2010; Yildiz and Pratt, 2006).
Another way to establish such relations would be the use of predefined
or automatically derived rule/patterns (Chang et al., 2012; Cou, 2010).
Currently, both strategies are used towards the extraction of biomedical
relations, either individually or combined (Xu and Wang, 2014). The pro-
posed algorithm utilizes co-occurrence based statistics to establish relations
between the biomedical terms on the large scale.
Co-occurrence
is meaningful
Usually, the main argument against the use of co-occurrence based statis-
tics is the quality or even existence of the returned associations in the
first place (Zweigenbaum et al., 2007). However, the analysis conducted
within this study suggests otherwise. The quality of the relations generated
is comparable to the quality of manually curated associations. As it has
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been shown (Chapter 4, Section 4.3.1.3) ontological profiles for genes and
drugs derived from textual co-occurrence demonstrate equal or at times
better performance than manually curated profiles. Similar is the finding
of Garten et al. (2010). The authors replace a manually curated drug gene
association network with a co-occurrence derived network and show that
the performance of their algorithm remains the same or even improves at
certain cases.
In an early study, Jenssen et al. (2001) build a gene-gene relationship net-
work by weighting the co-occurrences of gene-gene pairs in MEDLINE ab-
stracts. They state that the co-occurrences of biological entities in scientific
abstracts do reflect meaningful relationships, due to the condensed infor-
mation and clear statements of the research findings they contain. A recent
work also demonstrates that abstract level co-occurrence stronly correlates
with sentence level co-occurrence (Niu et al., 2010). Zhu et al. (2005)
attribute any false positive co-occurrence relationships to the errors intro-
duced by the Name Entity Recognition (NER) systems.
Underepresented
negative
associations
The co-occurrence degree is also proved to be correlated with the quality
of the association (Jenssen et al., 2001). Moreover, another study shows
that less than 10% of the sentences ”contains a modifier that radically influ-
ences the semantic content of the sentence”, meaning a hedgy expression
or a negation (Vincze et al., 2008). These facts explain why the perfor-
mance of CASSANDRA is hardly affected by any false positive relations
detected. Given that the negative associations are underepresented in lit-
erature (Pe´rez et al., 2004) and therefore would result to a low nPMI score,
no relevant filtering is necessary.
Co-occurrence
has high recall
Another reason for applying co-occurrence based statistics is their high
recall (Zweigenbaum et al., 2007). That is why, when combined with other
methodologies, there is a significant boost in the performance. Indicatively,
Aubry et al. (2006) demonstrate that introducing co-occurrence statistics
between genes and GO terms radically improves the gene functional anno-
tation. Seki and Mostafa (2007) build a network of genes, MeSH and GO
terms to discover indirect associations between genes and diseases. When
integrating textual co-occurrence from MEDLINE abstracts, the system’s
Chapter 5. Discussion 102
predictive power improves by 4.6%. Thereafter, co-occurrence based statis-
tics are at this point preferred over the supervised or not use of predefined
patterns/rules for the extraction of relationships between biomedical terms.
Scalability
Moreover, it is easier to apply co-occurrence methods on the large scale.
Using a mathematical schema to model co-occurrences is definitely more
straightforward than the application of pattern based stategies. Clearly,
the generation of patterns (especially when this is conducted manually)
is a laborious task (Huang et al., 2004). Additionally, it requires thor-
ough study of the respective domain. For example, in this study, were
for pattern-based approaches to be followed, 7 different syntactic patterns
would have to be generated corresponding to the 7 different types of rela-
tions, i.e., drug/gene-MeSH Disease, drug/gene-GO,MeSH Disease-MeSH
Disease, MeSH Disease-GO and GO- GO patterns. On the other hand,
co-occurrences are generally applicable (domain-independent) and need no
text-preprocessing (Zweigenbaum et al., 2007).
Type of
relation
Of course, co-occurrence based strategies do not provide the type of re-
lation and that is another argument against their usage. Indeed, when
focusing on first-order relation extraction (i.e., the relation between a term
A and a term B), it might be interesting to know the exact type of relation.
However, for second-order relation extraction (i.e., the ABC model) strate-
gies, such asCASSANDRA, even if the relations are known, they still have
to be concordant so as to generate a consistent hypothesis. In other words,
in both cases the hypotheses have to be further analyzed. However, in the
case of CASSANDRA nPMI already prioritizes the stronger hypotheses
and this significantly facilitates the procedure.
To sum up, co-occurrence based statistics have high recall, they are rela-
tively easy to apply on the large scale, they are domain-independent and
the associations they suggest do reflect meaningful relations between the
biomedical entities (Jenssen et al., 2001). The latter is also demonstrated
by the results of this very study; co-occurrence based profiles show a com-
parable or at times better performance than the manually curated profiles.
For these reasons, co-occurrence based statistics were at this point chosen
over the generation of syntactic patterns or rules towards the extraction
of relations. Still, we think that the two approaches are complementary
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and consider the use of patterns towards the refinement of drug gene as-
sociation hypotheses generated by CASSANDRA. Indicatively, there are
several works combining the two methodologies towards an enhanced qual-
ity of results (Xu and Wang, 2014; Bunescu et al., 2006).
5.3 The role of ontologies
Ontologies have a critical role in the representation of knowledge and the
dissemination of data in the biomedical domain. They are widely used in
data indexing and information retrieval (Whetzel et al., 2011), but also in
data integration and reasoning (Ashburner et al., 2000; Magka et al., 2014).
Therefore, it is fitting to utilize ontologies for connecting islands of drug
and gene data, as it is the task of this study. The arising question is which
is the most appropriate ontology for this task?
Why GO?
There is a plethora of biomedical ontologies of varied granularity and ded-
icated to different biomedical subdomains, (e.g., Barton et al. (2014) or
Zheng et al. (2013). Still, for the task at hand the goal is to focus on
the ontological terms that would be adequate to efficiently describe drugs
and genes, capture their functional properties and hence, ensure the suc-
cessful estimation of similarity between their profiles. In the case of genes
the decision is quite straightforward regarding the use of Gene Ontology
(Ashburner et al., 2000). Gene Ontology is an extensively used terminol-
ogy that addresses the need for consistent descriptions of gene products
across databases. It encompasses terms that represent biological processes,
cellular components and molecular functions. Obviously, these terms can
be used to build the context that encloses the processes and functionalities
which relate to drugs.
Why MeSH?
Evidently, drugs and genes are strongly related to diseases. Hence, the
use of terms stemming from a medical vocabulary, such as Medical Subject
Headings (MeSH ), is also suitable for their description. MeSH constitutes
a widely accepted use case of a clinical controlled vocabulary. It is manu-
ally curated, regularly updated and it is used to index the articles stored in
MEDLINE. Unlike other terminologies (e.g., LOINC or GALEN ), MeSH
is suitable for the task at hand because it focuses and has proven to be
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particularly successful towards medical literature retrieval (Nelson, 2009).
SNOMED CT, on the other hand, which is another popular terminology,
focuses on the representation and encoding of clinical data for the Elec-
tronic Health Records (EHR). Moreover, it contains concepts with subtle
differences in meaning which are difficult to discriminate (Chiang et al.,
2006). This can be partially attributed to post-coordination, meaning that
a concept can be coded by a coordination of different codes (Stevens and
Sattler, 2013). Although post-coordination confers a dynamic structure in
SNOMED CT, it also results in many ambiguous and context-dependent
concepts, the resolution of which requires the application of reasoning sys-
tems. MeSH, on the other hand, is a static terminology of readily available
terms.
Why only
Diseases?
MeSH contains 16 trees overall and more than 27, 000 terms (descrip-
tors). Apart from the Diseases tree, MeSH includes categories such as
Phenomena and Processes, Information Science, Publication Characteris-
tics, Geographicals or Disciplines and Occupations. The majority of them
is not relevant and, thus, constitutes a source of error for text mining. On
the other hand, GO is also large, but entirely focused on the biological
processes and functions. For that reason, GO was fully used, whilst from
MeSH only the Diseases tree was utilized.
GO
outperforms
MeSH
Diseases
Clearly, the application of MeSH Diseases and GO terms has proven suc-
cessful towards the drug gene association prediction from literature, as
shown by the overall performance of CASSANDRA (Chapter 4). More
specifically, GO successfully discriminates true from false drug gene asso-
ciations even when the literature for the respective entities is limited (see
Section 4.3.1.1). Co-occurrence based profiles containing GO terms also
perform better than manually curated MeSH Disease profiles, illustrating
that the type of terms plays a significant role towards the establishment of
associations. But what is special about GO terms? GO is entirely dedi-
cated to the sufficient and accurate representation of genes, gene products
and their attributes. Hence, the terms included in GO are by nature highly
descriptive and precise. MeSH Diseases, on the other hand, constitute con-
cepts of a broader perspective, i.e, a disease encompasses a set of functions,
processes, signs and symptoms to which many drugs and genes could be
associated. That difference between the two terminologies is reflected on
the algorithmic performance.
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5.3.1 Estimating the semantic similarity
The means to estimate the semantic relatedness between a drug and a
gene ontological profile is critical towards assessing the strength of the drug
gene association. Hence, which is the most appropriate semantic similarity
metric for the task at hand?
CASSANDRA utilizes the statistical semantic similarity, meaning the
normalized Pointwise Mutual Information (nPMI ). nPMI is a fully corpus-
based, probabilistic measure that treats the ontological concepts just as
a set of terms. The similarity between two concepts is estimated solely
based on the degree of their co-occurrence in MEDLINE indexed titles and
abstracts.
Ontology
independence
One major advantage of nPMI over other similarity metrics is its general
applicability. Several metrics are built to explicitly identify relations be-
tween terms of a specific ontology (e.g., GO as in Yang et al. 2012; Jain and
Bader 2010). For example, Wang et al. (2007) propose a metric wherein
they exploit the GO is part of and is a relations. On the contrary, nPMI
is ontology-independent and can be applied on both MeSH Diseases and
GO terms or any other ontologies incorporated in the algorithm in the
future.
Capturing
latent relations
To assess the efficiency of nPMI , we compared the metric to two tra-
ditional measures of semantic similarity, i.e., Wu-Palmer (1994) and Lin
(1998). As shown in the results (Chapter 4, Section 4.3.2) nPMI demon-
strated the best performance, in terms of Area Under the Curve, Precision-
Recall and discriminative power. Unlike the Wu-Palmer and Lin metrics,
nPMI can capture the similarity between terms that belong to different
subontologies or even different ontologies, e.g., terms from GO Biologi-
cal Process and GO Molecular Function or GO and MeSH Disease terms.
Furthermore, the application of nPMI enables the identification of latent
relations between ontological terms that do not necessarily occur very fre-
quently in text. This is of particular importance, since the goal of CAS-
SANDRA is to uncover the hidden information that lies behind unknown
drug gene associations.

Chapter 6
Conclusion
This chapter discusses the contribution and future directions of CASSAN-
DRA. It summarizes the important findings of this study and proposes
certain steps towards the improvement and expansion of the suggested
methodology.
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6.1 Contribution
The current thesis introduces CASSANDRA. An unsupervised corpus-
based algorithm that addresses the prediction of drug gene associations
from literature. The algorithm is an extended version of traditional Litera-
ture Based Discovery. It explores the biomedical literature and interrelates
drug to genes via intermediate ontological concepts.
In a nutshell,
• 23, 487, 871MEDLINE abstracts and titles were annotated with drugs,
genes, GO and MeSH Disease terms
• co-occurrence based profiles were precomputed for 2, 837 drugs and
57, 395 genes
• 5 new drug gene association datasets were compiled to systematically
assess the algorithm’s efficacy
• overall 37, 603, 728 distinct drug gene associations were scored
Use of nPMI
The method generates co-occurrence based concept profiles for both drugs
and genes. Normalized Pointwise Mutual Information (nPMI ) is used to
create the profiles by finding statistical significant associated ontological
terms in MEDLINE titles and abstracts. nPMI is also utilized as measure
of semantic similarity to estimate the relatedness between drugs and genes
via their profiles.
Good
performance
The application of CASSANDRA towards drug gene association pre-
diction and the identification of drug repurposing cases has been demon-
strated. Regarding the drug gene association prediction, the performance
of the algorithm is evaluated on 6 datasets. It has to be pinpointed that
all drug-gene pairs consisting of co-occurring drugs and genes are removed
from the datasets. Results show that the suggested method is robust and
its performance is independent from the size and type of the dataset. No-
tably, CASSANDRA achieves an AUC up to 0.88 in prioritizing true
associations between Approved drugs and Human genes. Considering the
overoptimistic results provided by supervised techniques which reach at
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times an AUC up to 0.93 (Pahikkala et al., 2014), CASSANDRA’s per-
formance is quite striking.
Co-occurrence
produces
meaningful
predictions
The evaluation revealed further interesting properties of CASSANDRA.
First, it can successfully prioritise direct (i.e., physically binding) from in-
direct drug gene associations, as shown by the AUC values obtained on
the datasets CTDBinding and CTDRelated . Second, the use of co-occurence
based profiles derived from literature doesn’t affect at all the performance
of CASSANDRA. In particular, when using GO terms, the co-occurrence
based profiles outperformed the manually curated MeSH Disease profiles.
This suggests that the co-occurence based profiles derived from the biomed-
ical literature are indeed reliable for associating drugs to genes.
Textual
evidence
confirm
predictions
With regards to drug gene association prediction, three prediction cases
were further analyzed. Two of them correspond to the drugs Cathine and
Fenethylline for which there are no known targets, so far. CASSANDRA
predicts two strongly associated genes, one for each drug; GHRL and ApoE
respectively. The predicted genes rank among the first 0.4 % of the ordered
list of genes scored against each drug. To assess the quality of these predic-
tions, we digged into the literature and manually retrieved concrete pieces
of evidence which indeed suggest that the respective associations are mean-
ingful. An additional case study was investigated in the same fashion, this
time between the known drug Milnacipran and its known associated gene
SLC6A4 that codes for its target. The results reveal that CASSANDRA
did consider the new therapeutic indication Fibromyalgia for the establish-
ment of the association, despite the fact that the drug’s efficacy on the
respective disease was at the time unknown.
New
therapeutic
indications
The efficacy of CASSANDRA towards drug repurposing was further
evaluated. A dataset comprising all known drug repositioning cases that
were FDA approved within the last 5 years was compiled. For these drugs
the generated profiles are based on the literature data before the year of
approval of each repositioning case. We demonstrated that the respective
profiles always include the new indications, and that in the majority of the
cases these indications are ranked high among drugs’ profile terms.
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6.2 Future directions
Improve
annotation
There are certain directions to improve further the results generated by
CASSANDRA. The first is to alleviate the error introduced by the annota-
tion methodologies which are responsible to a big extent for the existence
of false positive drug gene associations (Zhu et al., 2005; Jenssen et al.,
2001). Perhaps the use of additional annotators could further enhance the
quality of results if the interagreement space of them were to be considered.
More chemical
dictionaries
Towards the same direction, an interesting extension is to use more drug/-
compound related dictionaries. CASSANDRA is currently limited only
in drugs reported in the DrugBank database. Although DrugBank consists
a high quality resource of drug target interaction data and the respective
in-house dictionary demonstrates high performance, still there is the pos-
sibility to harness new chemical taggers that have been recently developed.
For example, ChemSpot by Rockta¨schel et al. (2012) or OSCAR4 by Jes-
sop et al. (2011) have shown encouraging results towards the annotation
of chemicals in text. The tricky issue of the recognition of IUPAC drug
names in text is not extensively studied but there are also some works
that CASSANDRA could benefit from, such as the supervised approach
proposed by Klinger et al. (2008).
Integrate the
profiles
Regarding the profile generation, as shown in Chapter 4, the co-occurrence
based profiles proved highly efficient. However, one could not deny that
the information existing in public repositories is also of value and can con-
tribute to the generation of high quality drug gene association hypotheses.
Consequently, a further improvement would be to enhance the quality of
the profiles with ontological concepts found in biomedical repositories. For
example, it would be interesting to investigate whether the performance im-
proves if the manually curated and co-occurrence based profiles are merged
in the case of MeSH Diseases. Regarding GO terms, the Gene Ontology
Annotation (GOA) could also enhance the profiles with interesting associ-
ations. Moreover, the profiles of drugs and genes could be also enriched
with physicochemical properties and additional protein structural informa-
tion respectively. Another suggestion would be to exploit pharmacogenomic
data that is aggregated and represented in the form of networks (Daminelli
et al., 2012).
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Mine a
different text
Abstracts and titles from MEDLINE have proven a high quality resource
for the identification of relationships between the biomedical entities. How-
ever, despite the limited space of available full-text articles (Thomas et al.,
2012), it would be interesting to examine if the they provide relations that
can further improve the prioritization of drug gene associations. Neverthe-
less, this has to be taken with a grain of salt, since the percentage of ”nega-
tion” and hedgy sentences increases in the article bodies (Fontelo et al.,
2013). So far, CASSANDRA utilizes co-occurrences on the abstract-level.
An interesting expansion is to take one step further and use sentence-level
co-occurrence information. Although the majority of biomedical entities
co-occurring in abstracts, also co-occur in sentences (Niu et al., 2010) and
hence recall remains unaffected, still an increase in the precision would be
expected. Of course, in such a case the whole application of the nPMI
model would have to be reformulated.
Pattern/rule
application
The next step towards literature-based drug gene association prediction
would be the use of patterns/rules that would interpret the hypotheses.
A rough suggestion is to automatically retrieve the text in between the
biomedical entities, which then in turn can be either inspected manually
or mined to extract explicit associations. However, such an extension is far
more feasible if automatic pattern generation is followed, since patterns are
domain dependent and laborious to create. Nevertheless, the use of pat-
terns isn’t enough to consolidate a drug gene association derived from text.
Rule based approaches to unravel the concordant relations could alleviate
the problem, but also add to the complexity of the task significantly.
Complementarity
with other
approaches
Is it worthy to seek such a laborious and complicated direction to fur-
ther establish the hypotheses that CASSANDRA generates? The as-
sociations provided by CASSANDRA are derived from text. They are
in fact the representation of a signal that a drug and a gene are poten-
tially associated. Instead of dedicating hours of research in literature to
discover hidden relations and common islands of data between drugs and
genes, CASSANDRA speeds up the process and produces the respective
signal. That is, by nature, complementary evidence to other approached
towards drug-target interaction prediction. The results of CASSANDRA
can be furtherly examined via large scale molecular docking analysis as in
Li et al. (2011). Lately, these approaches become more and more popu-
lar. In a recent study, it is suggested that the binding site similarity is
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the key to identify promiscuous drugs and boost drug repurposing. (Haupt
et al., 2013). CASSANDRA could significantly benefit from such analy-
ses towards the refinement of the proposed associations without necessarily
having to further process the text that underlies them.
Chapter 7
Supplementary Material
Table 7.1: Arithmetic means for different semantic similarity metrics
nPMI Lin Wu-Palmer
DrugBankApproved true 0.553 0.730 0.835
false 0.306 0.487 0.625
distance 0.247 0, 243 0, 210
DrugBankExperimental true 0.358 0.470 0.601
false 0.306 0.489 0.622
distance 0, 052 −0, 019 −0, 021
Y amanishi true 0.590 0.771 0.876
false 0.486 0.722 0.841
distance 0, 104 0, 049 0, 035
The table shows the arithmetic means for the score distributions of true and
false drug gene associations that every metric of semantic similarity achieves
on the respective dataset. The difference between the means of true and false
distribution is provided. Clearly, nPMI achieves the highest difference on every
dataset. When applied on the DrugBankExperimental dataset, Wu-Palmer and
Lin completely fail the discrimination task.
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Figure 7.1: All ratios PR curves for all datasets
All PR curves for different ratios of imbalance between true and false drug
gene associations contained in the evaluation datasets are shown. The curves
are consistent with the respective ROC curves. Again, CASSANDRA per-
forms better on the datasets DrugBankApproved and CTDBinding than the Drug-
BankExperimental and CTDRelated respectively. Increasing the number of false
drug gene associations significantly affects the DrugBankExperimental due the
highly similar score distributions that exist between true and false drug gene
pairs.
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Figure 7.2: All ratios PR curves - Manually curated vs. co-occurrence
based profiles
All PR curves for different ratios of imbalance between true and false drug gene
associations are shown. Co-occurrence based profiles of GO terms demonstrate
the best performance across all ratios. Manually curated MeSH Disease profiles
perform similar to the co-occurrence joined profiles. Doubling or quadrupling
the size of false drug gene associations doesn’t affect significantly the algorithm’s
efficacy.
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